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Diabetes mellitus is a group of metabolic disorders caused by a relative or
absolute lack of insulin. Currently, 23.6 million Americans have diabetes. Diabetes can
lead to serious microvascular and macrovascular complications, such as cardiovascular
disease, blindness, kidney disease, lower-limb amputations, and premature death. Due to
the potential cardiovascular complications and the high prevalence of co-morbid
hypertension and/or hyperlipidemia in patients with diabetes, diabetes management
should include close monitoring of blood glucose, blood pressure, and cholesterol levels.
Medical management of diabetic patients is costly; approximately 1 in every 10
health care dollars is currently spent treating diabetes. Studies have shown that in
chronic conditions such as diabetes, increased medication use results in demonstrable
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improvements in health outcomes, reduced hospitalization rates, and decreased direct
health care costs. To date no studies have evaluated the impact of a pharmacist-led
intervention on diabetic medication adherence.
The purpose of this investigation was to analyze the impact of a pharmacist-led
medication management program on medication adherence and pharmacy costs and to
evaluate clinical measures of diabetes, hypertension, and hyperlipidemia. This study was
a quasi-experimental, longitudinal, pre-post study, with a control group. Scott & White
Health Plan (SWHP) patients with diabetes (type 1 or type 2), poor glycemic control
(most recent A1C >7.5%), and living within 30 miles of participating pharmacies were
invited to participate in the intervention which consisted of monthly appointments with a
clinical pharmacist and a co-payment waiver for all diabetes medications and testing
supplies. A total of 118 patients met study inclusion criteria and were enrolled in the
intervention between August 2006 and July 2008. Intervention patients were matched on
sex and age to SWHP patients with poor diabetes control living more than 30 miles from
a participating pharmacy. To measure the impact of the intervention, medical and
pharmacy data were evaluated for one year before and after the study enrollment date.
A significant difference was seen in the percentage of patients with type 1
diabetes in the intervention group (14) and the control group (3). The medication
management program significantly improved A1C levels in intervention patients relative
to controls (-1.1% vs. 0.6%) and was more effective in lowering A1Cs in type 2 diabetics
than type 1 patients. Although the generalized linear model did not show that the
intervention significantly improved the percentage of patients achieving the ADA goal
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A1C of <7% compared to controls, the multivariate logistic regression, which controlled
for factors such as diabetes type, showed that patients participating in the intervention
were 8.7 times more likely to achieve the A1C goal. Persistence with diabetic
medications and the number of medications taken significantly increased in the
intervention group; however, adherence rates, as measured by medication possession
ratio (MPR), did not significantly improve relative to controls. The expenditure on
diabetic medications and testing supplies increased substantially more in the intervention
group than in the control group.
The percentage of patients adherent with antihypertensive medications (MPR
≥80%) increased from 76% to 91% in the intervention group and decreased from 68% to
63% in the control group (P<0.05); no significant difference in blood pressure control
was observed. For hyperlipidemia medications, adherence and persistence increased and
pharmacy costs decreased in both groups, likely due to the introduction of the first
generic HMG-CoA reductase inhibitor into the market during the study period. Future
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Epidemiology of Diabetes Mellitus
Diabetes mellitus is a group of metabolic disorders caused by a relative or
absolute lack of insulin, a hormone that is needed to convert sugar, starches, and other
food into energy needed for daily life.1,2 In response to an increase in blood sugar (for
example, after ingestion of food), insulin stimulates muscle and fat cells to remove
glucose from the blood and stimulates the liver to metabolize glucose, causing blood
sugar to return to normal levels.3 Without adequate insulin, diabetics experience chronic
hyperglycemia, which is associated with long-term damage, dysfunction, and failure of
multiple organs.4 Insulin deficiency may result from a defect in insulin secretion, insulin
sensitivity, or both.5
Currently, 23.6 million Americans have diabetes, a total which is 8% of the U.S.
population. While most diabetics are aware of their condition, about 5.7 million are
unaware that they have the disease, and therefore, are not receiving proper medical
treatment. Even more alarming is the fact that an additional 57 million Americans are
currently pre-diabetic, meaning that if significant lifestyle modifications are not made,
those individuals will also become diabetic in the future.2 Current projections suggest
that by 2050, the prevalence of diabetes in the U.S. will increase to 39 million people.6
Diabetes is classified as type 1, type 2, gestational, or “other,” based on the
underlying cause of the disorder. Gestational diabetes occurs in approximately 4% of
pregnancies. As the name suggests, gestational diabetes is a glucose intolerance that
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begins or is first recognized during pregnancy. In most cases, glucose regulation returns
to normal after delivery, but approximately 5-10% of women with gestational diabetes
are found to have type 2 diabetes after pregnancy.2,4 A recent meta-analysis by Bellamy
et al. (2009) reported that women with gestational diabetes have a seven-fold increased
risk of subsequent development of type 2 diabetes compared to those who maintained
normal glycemic levels during pregnancy.7 “Other” types of diabetes are rare and include
cases that arise from the mutation of a single gene.4 As the vast majority of diabetic
patients have type 1 or type 2 diabetes, this thesis will focus solely on the treatment of
these two forms of the disorder.
Type 1 Diabetes
Type 1 diabetes results from autoimmune destruction of the pancreatic β-cells and
accounts for 5-10% of cases.1 The rate of β-cell destruction varies between individuals
but is commonly rapid in infants and children and slower in adults.4 Patients with type 1
diabetes generally present with moderate to severe polyuria, polydipsia, polyphagia,
fatigue, weight loss, and sometimes blurred vision. At the time of presentation, patients
generally have little or no pancreatic reserve, are prone to develop ketoacidosis, and
require exogenous insulin to sustain life.1
While type 1 diabetes develops most often in children, the disease can occur at
any age, is equally likely to affect males and females, and is more common in whites than
in nonwhites.4 A genetic predisposition associated with type 1 diabetes is seen, and these
patients are prone to other autoimmune disorders, such as Graves’ disease, Hashimoto’s
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thyroiditis, Addison’s disease, vitiligo, and pernicious anemia.4 In addition, type 1
diabetes is thought to be related to environmental factors that are still poorly defined.
Type 2 Diabetes
Type 2 diabetes accounts for about 90% of cases and is characterized by increased
hepatic glucose production, resistance to insulin action, obesity, and β-cell dysfunction.1
A strong genetic predisposition is associated with this type of diabetes, which is more
significant than that seen with type 1 diabetes. Minority populations, such as Hispanics,
African Americans, and Native Americans, have a higher prevalence of diabetes and
experience a higher rate of diabetic complications than white counterparts.8 Individuals
who develop type 2 diabetes commonly have a history of gestational diabetes,
hypertension, and/or dyslipidemia. The risk of developing type 2 diabetes increases with
age, weight, and lack of physical activity.4
Type 2 diabetes generally develops slowly and commonly goes undiagnosed for
many years, because early stages of the disorder are often not severe enough for the
patient to notice or recognize the classic signs of hyperglycemia, such as polydipsia,
polyuria, and fatigue.4 Many patients are asymptomatic at the time of diagnosis;
however, some present with advanced complications, particularly neuropathy.5
The prevalence of type 2 diabetes is growing worldwide, largely as a consequence
of a sedentary lifestyle, increased consumption of energy-dense foods, increased obesity,
and an aging population.9,10 The World Health Organization predicts that the number of
diabetics worldwide will increase from 143 million in 1997 to 300 million in 2025.10
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Previous studies have shown that the risk of diabetes is directly related to body weight,
with each kilogram increase in weight increasing the risk of diabetes by an estimated 4.5-
9%.8,11 Conversely, intentional weight loss by overweight men and women has been
shown to decrease the risk of developing type 2 diabetes; for every 20 pounds lost, the
rate of diabetes decreases by 11% and 17% for men and women, respectively.12
Burden of Illness
Diabetes can lead to serious microvascular and macrovascular complications,
such as cardiovascular disease, blindness, kidney disease, lower-limb amputations, and
premature death. According to the CDC, diabetes was the seventh leading cause of death
listed on U.S. death certificates in 2006. However, studies have found that only about
35-40% of decedents with diabetes have diabetes noted on the death certificate, therefore,
the death rate due to diabetes is likely underreported.13 Overall, the risk of death for
diabetics is approximately twice that of individuals of similar age without diabetes.13
Diabetic patients have a 2-4 fold increased risk of heart disease and stroke, and
about two-thirds of diabetics have hypertension and some degree of nervous system
damage. Diabetes is the leading cause of adult blindness and end-stage renal disease and
is responsible for more than half of all lower limb amputations. Abnormalities of
lipoprotein metabolism and periodontal disease are also common in diabetics. The
physical and emotional impact of diabetes and the demands of therapy may cause
significant stress in patients.2
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Medical management of diabetic patients is costly. In 2007, total direct and
indirect costs of diabetes treatment were estimated to be $174 billion per year in the
United States. Approximately two-thirds was due to direct medical costs, while $58
billion was attributed to indirect costs such as increased absenteeism, reduced
productivity, disease-related unemployment disability, and productivity loss due to early
mortality. The $174 billion is an underestimate of the actual cost of diabetes, however,
because the total omits the cost of intangibles such as pain and suffering, care provided
by non-paid caregivers, and excess medical costs associated with undiagnosed diabetes.2
The annual per capita cost of health care for diabetic patients in 2007 in the U.S.
was $11,744, with more than half of the money spent directly on diabetes care. On
average, the cost of treating a patient with diabetes is 2.3 times greater than the cost of
treating a non-diabetic patient. Given the high prevalence of diabetes in the United
States, approximately 1 in every 10 health care dollars is currently spent treating
diabetes.2 Therefore, any intervention saving even a small amount of money on a per
capita basis for diabetic patients could potentially have a major impact on national health
care spending.
Diabetes Treatment Guidelines
The American Diabetes Association (ADA) publishes evidence-based standard of
care guidelines as a resource for healthcare professionals treating diabetic patients.
Diabetes management encompasses more than blood glucose control, as two out of three
patients with diabetes die from heart disease or stroke.2 Therefore, blood pressure and
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cholesterol should also be carefully monitored in diabetic patients. With the care of the
patient as a whole in mind, the ADA guidelines provide information that encompasses all
aspects of care, from diagnosing patients to treatment of diabetes-related complications
and third-party reimbursement. Although specific patient characteristics, such as patient
age, co-morbid conditions, and past medical history, may require modification of
treatment goals, the ADA guidelines provide target measures that most diabetic patients
should strive to achieve. A brief summary of the clinical treatment guidelines relevant to
this study is provided below.
Diabetes Care
Diabetic patients should receive collaborative medical care from a health care
team which may include physicians, nurse practitioners, physician assistants, nurses,
dieticians, and/or pharmacists. A comprehensive diabetes evaluation should be
performed at the first medical encounter in order to understand the patient’s current
health status and formulate a plan to ensure optimal management of the patient (Table
1.1).
The health care team and the patient should create a management plan that is
individualized for the patient, taking into consideration their physical, emotional, and
social situation. Each management plan should include diabetes self-management
education (DSME), as patients must take an active role in their care. Patients should
clearly understand treatment goals, and these goals should be obtainable given each
patient’s unique circumstances.
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Table 1.1 Components of the Comprehensive Diabetes Evaluation
Medical History
 Age and characteristics of onset of diabetes (e.g., DKA, asymptomatic laboratory
finding)
 Eating patterns, physical activity habits, nutritional status, and weight history;
growth and development in children and adolescents
 Diabetes education history
 Review of previous treatment regimens and response to therapy (A1C records)
 DKA frequency, severity, and cause
 Hypoglycemic episodes
o Hypoglycemic awareness
o Any severe hypoglycemia: frequency and cause
 History of diabetes-related complications
o Microvascular: retinopathy, nephropathy, neuropathy (sensory, including
history of foot lesions; autonomic, including sexual dysfunction and
gastroparesis)
o Macrovascular: CHD, cerebrovascular disease, PAD
o Other: psychosocial problems,* dental disease*
Physical Examination
 Height, weight, body mass index
 Blood pressure determination, including orthostatic measurements when indicated
 Fundoscopic examination*
 Thyroid palpation
 Skin examination (for acanthosis nigricans and insulin injection sites)
 Comprehensive foot examination:
o Inspection
o Palpation of dorsalis pedis and posterior tibial pulses
o Presence/absence of patellar and Achilles reflexes
o Determination of proprioception, vibration, and monofilament sensation
Laboratory Evaluation
 A1C, if results not available within past 2-3 months
If not performed/available within past year:
 Fasting lipid profile, including total, LDL- and HDL-cholesterol and triglycerides
 Liver function tests
 Test for urine albumin excretion with spot urine albumin/creatinine ratio
 Serum creatinine and calculated glomerular filtration rate (GFR)
 Thyroid-stimulating hormone in type 1 diabetes, dyslipidemia or women over age 50
Referrals
 Annual dilated eye exam
 Family planning for women of reproductive age
 Registered dietitian for medical nutrition therapy (MNT)
 Diabetes self-management education
 Dental examination
 Mental health professional, if needed
*See appropriate referrals for these categories.
Source: American Diabetes Association. Standards of Medical Care in Diabetes – 200914
DKA = diabetic ketoacidosis; CHD = coronary heart disease; PAD = peripheral arterial disease
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Glycemic control is a key component of diabetic treatment. Glycemic control can
be measured using two methods: self-monitoring of blood glucose (SMBG) or a test of
glycosylated hemoglobin A1C.
The frequency and timing of SMBG depends on the individual. Most insulin-
using patients should test their blood glucose three or more times daily to reach A1C
goals safely without hypoglycemic episodes, whereas the utility of frequent SMBG in
non-insulin patients is less certain. All patients should have their SMBG technique
evaluated, both initially and at regular intervals thereafter. In addition, patients must be
taught how to use the SMBG data to appropriately adjust food intake, exercise, or
pharmacological therapy to achieve specific glycemic goals. The ability to correctly
obtain and use SMBG data should be reevaluated periodically.
The glycosylated hemoglobin (A1C) assay, a time-weighted average of the mean
daily blood glucose over the previous three to four months, is the most widely used and
reliable means of assessing chronic glycemia in order to make treatment
modifications.15,16 The correlation between A1C and mean blood glucose is presented in
Table 1.2.
Table 1.2. Correlation of A1C with Mean Blood Glucose








Source: ADA treatment guidelines (2009)14
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All patients should have A1C testing performed routinely. The frequency of the
A1C test depends on the clinical control of the patient, the treatment regimen used, and
the judgment of the clinician. In patients who have stable glycemic control and are
meeting treatment goals, the A1C test should be performed a minimum of two times a
year, whereas, patients not achieving treatment goals and/or whose therapy has changed
should have the A1C test quarterly.
The A1C goal for most adults is <7%. This goal is based on studies which show
that lowering A1C to below or around 7% reduces microvascular, macrovascular, and
neuropathic complications in type 1 and type 2 diabetes. However, less stringent A1C
goals may be appropriate for patients with any of the following:
 History of severe hypoglycemia
 Limited life expectancy
 Advanced microvascular or macrovascular complications
 Extensive co-morbid conditions
 Inability to attain A1C <7% despite DSME, appropriate glucose monitoring,
and effective doses of multiple glucose-lowering agents, including insulin
The self-monitored blood glucose goal should be a preprandial blood glucose of
70-130 mg/dL and peak postprandial blood glucose <180 mg/dL; both values should be
measured 1-2 hours after the beginning of a meal.14
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Blood Pressure Control
Hypertension is a common co-morbid condition in patients with diabetes. Blood
pressure increases when arteries are narrowed and blood flow is restricted. Arterial
narrowing may be caused by atherosclerosis, the accumulation of cholesterol, or
chronically elevated blood glucose levels. Proper blood pressure control in diabetic
patients decreases cardiovascular disease by 33% to 50% and microvascular disease by
approximately 33%. Research has shown that for each 10 mmHg reduction in systolic
blood pressure, the risk for any complication related to diabetes is reduced by 12%.13
For most adults, normal blood pressure is defined as <120/80 mmHg and
individuals with a blood pressure ≥140/90 mmHg on two or more consecutive occasions
are diagnosed with hypertension. The clinical categories and measurement values for
hypertension established by the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) are
presented in Table 1.3.
Table 1.3. Classification of Blood Pressure for Adults Aged ≥18 Years
Blood Pressure Classification† SBP (mmHg) DBP (mmHg)
Normal <120 <80
Prehypertension 120-139 80-89
Stage 1 hypertension 140-159 90-99
Stage 2 hypertension ≥160 ≥100
Source: Chobanian (2003)17
SBP = systolic blood pressure; DBP = diastolic blood pressure
†If SBP and DBP numbers are not in the same category, the patient is classified as the more severe category.
Due to the synergistic risks of hypertension and diabetes, the diagnostic cutoff for
hypertension is 10 mmHg lower for patients with diabetes than non-diabetics (≥130/80
vs. ≥140/90, respectively). Similarly, blood pressure goals are 10 mmHg lower for
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people with diabetes or chronic kidney disease, who have a BP goal of <130/80 vs.
<140/90 for non-diabetic adults.14
The ADA recommends that most adults with diabetes who have risk factors for
CAD, PVD, hypertension, or heart attack should take an 81 mg dose of aspirin daily. In
addition, several lifestyle behaviors are recommended in order to treat and prevent
hypertension including:17
 Maintaining a healthy body weight
 Exercising regularly
 Eating a healthy diet, low in saturated fat, total fat, cholesterol, and sodium
and rich in vegetables, fruit, and nonfat dairy, commonly referred to as the
DASH (Dietary Approaches to Stop Hypertension) diet
 Quitting smoking
 Keeping alcohol intake at a moderate level
 Practicing good stress management
According to the ADA diabetes treatment guidelines, patients with blood
pressures >140/90 should initiate pharmacologic therapy in addition to lifestyle therapy.
Most hypertensive patients will require more than one antihypertensive medication to
achieve their target blood pressure.17 Patients with mildly elevated blood pressures (130-
139/80-89) should initiate lifestyle therapy. If blood pressures remain elevated (>130/80)






















*The pharmacologic therapy regimen should include an angiotensin converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB). A diuretic may be added to achieve blood
pressure targets; use a thiazide diuretic in patients with an estimated GFR ≥30 mL/min per 1.73 m2
and a loop diuretic in patients with an estimated GFR <30 mL/min per 1.73 m2.
Source: ADA treatment guidelines (2009)14
Figure 1.1. Algorithm for Treatment of Blood Pressure in Diabetic Patients
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Blood pressure control is critical because hypertension increases the risk of
macrovascular and microvascular complications in diabetic patients. Insulin resistance is
a common underlying mechanism for both hypertension and diabetes.18 In addition,
diabetic patients have lower threshold levels for hypertension diagnosis. Therefore, it is
not surprising that hypertension is more common in diabetics than among the general
population. According to the Centers for Disease Control and Prevention, 75% of adults
with self-reported diabetes in 2003-2004 had a blood pressure greater than or equal to the
recommended 130/80 mmHg or used prescription medication for hypertension, while the
National Health And Nutrition Examination Survey (NHANES) reported a prevalence of
hypertension of 29.6% among all adults during that same year.13,19
Lipid Management
According to the ADA treatment guidelines, most diabetic patients should have
cholesterol measured annually, whereas adults with known low-risk lipid values (LDL
cholesterol <100 mg/dL, HDL cholesterol >50 mg/dL, and TG <150 mg/dL) may be
tested every 2 years.14 The National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III [ATP III]) has established clinical practice guidelines for
cholesterol treatment. The recommended cholesterol levels in these guidelines are
represented in Table 1.4.20
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Table 1.4. ATP III Cholesterol Goal Levels





Source: NCEP ATP III Guidelines (2002)20
†LDL <100 mg/dL is the goal for patients with coronary heart disease (CHD) or a
CHD risk equivalent (i.e. diabetes)
The ADA recommends a LDL cholesterol goal level of <100 mg/dL for most
patients with diabetes. However, recent clinical trials have shown that high-risk patients,
such as those with acute coronary syndromes or previous cardiovascular events, have a
significant reduction in further events when more aggressive therapy, aimed to achieve a
LDL cholesterol of <70 mg/dL, is implemented. Therefore, the ADA supports an
optional goal of <70 mg/dL in very high-risk diabetic patients with overt CVD.14
While high HDL cholesterol levels (≥60 mg/dL) are ideal in that they are
considered a “negative risk factor,” patients with diabetes are likely to have lower than
normal HDL levels and LDL cholesterol control is the source of primary concern in
diabetic patients.20 Therefore, the ADA recommends a lower HDL cholesterol goal level
of >40 mg/dL for males and >50 mg/dL for females with diabetes.14
Similar to the treatment and prevention of high blood pressure, lifestyle
recommendations for hyperlipidemia include: exercise, weight loss (if indicated),
smoking cessation, and a healthy diet low in saturated fat, trans unsaturated fat, and
cholesterol.14 Unlike treatment of hypertension, however, pharmacologic treatment is
recommended in certain diabetic patients, regardless of patient cholesterol serum
concentrations. The ADA recommends HMG-CoA reductase inhibitor (“statin”) therapy
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in addition to lifestyle change for all diabetic patients with overt CVD and for diabetic
patients without CVD who are over the age of 40 and have one or more CVD risk
factors.14
Medication Adherence
Adherence, compliance, and persistence are three commonly used terms for
describing medication-taking behavior. Adherence is defined by the World Health
Organization21 as “the extent to which a person’s behavior – taking medication, following
a diet, and/or executing lifestyle changes corresponds with agreed recommendations from
a health care provider.” The terms “adherence” and “compliance” are nearly
synonymous. The term “compliance” has fallen into disfavor in recent years, however,
because the term suggests a patient is passively and submissively following a physician’s
orders. The more-positive connotation of “adherence” suggests the patient has a
collaborative partnership with the healthcare provider and is actively involved in
treatment.22 “Persistence” is defined as the ability of a patient to take medication for the
intended course of therapy, or operationally as the duration of time from initiation to
discontinuation of therapy.23,24 For patients with chronic conditions such as diabetes, the
intended course of therapy is often the person’s lifetime.
Medication adherence and persistence rates are generally higher among patients
with acute compared to chronic conditions. While most patients will complete a course
of therapy for acute conditions, several studies have shown that persistence with
16
medications for chronic conditions drops dramatically after the first six months of
therapy.25,26
Medication nonadherence is a significant problem worldwide. According to a
recent report by the World Health Organization, adherence to long-term therapy for
chronic illnesses averages only around 50% in developed countries and is even lower in
developing countries. A growing body of adherence research evidence suggests that
since the problem of nonadherence is widespread and can have such detrimental effects
on patient health and quality of life, more health benefits would result from improving
adherence to existing treatments than would result from developing new therapies.21
Consequences of Nonadherence
Several studies have demonstrated that nonadherence with medication results in
increased use of medical resources, such as physician visits, laboratory tests, emergency
department visits, and hospital admissions.27,28 A retrospective cohort analysis by Sokol
et al. (2005) of U.S. adults with hypertension, diabetes, or hyperlipidemia showed an
inverse relationship between medication adherence and risk of disease-related hospital
admissions; for all three conditions, a significantly decreased risk of hospitalization was
observed in patients with high levels of adherence (80-100%) compared with less-
adherent patients (Figure 1.2).29 Similarly, Ho et al. (2006) found medication
nonadherence to be associated with a 58% increased risk of all-cause hospitalization and
an 81% increased risk of all-cause mortality in patients with type 2 diabetes.30
An estimated 125,000 deaths occur each year in the U.S. due to nonadherence
with cardiovascular medications alone.31 Considering all health conditions,
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nonadherence is estimated to be responsible for 33-69% of all medication-related hospital
admissions and to cost the U.S. health care system $100 billion annually.25,27






































Note: Adherence defined as the percentage of days during the 12-month analysis period that patients had a
supply of one or more maintenance medications for the condition (based on “days’ supply” in the patients’
prescription claim records)
Factors Related to Adherence
Nearly 200 unique doctor-, patient-, and encounter-related variables have been
studied to date to evaluate the complex phenomenon of medication-taking behavior and
to identify and address barriers. However, none have been found to fully explain or
predict medication adherence.22 Ingersoll and Cohen (2008) recently published a review




diabetes, HIV, chronic pain, mental disorders, and cardiovascular disease, and found that
although the quantity and strength of evidence in the literature varied among the
conditions, overall, patients tended to have better adherence when medication regimens
were simplified (e.g., once-daily dosing vs. twice-daily dosing) and when patients clearly
understood how and when to properly take medications.32 Other common reasons for
medication nonadherence found in the literature are provided in Table 1.5.
Table 1.5 Predictors of Medication Nonadherence
 Low literacy/limited English language proficiency
 Homelessnesss
 Substance abuse
 Psychiatric disease (e.g. depression, anxiety)
 Lower cognitive function or cognitive impairment
 Forgetfulness
 Lack of insight into illness
 Lack of belief in benefit of treatment
 Belief medications are not important or are harmful
 Inconvenience of medication regimen
 Side effects or fear of medication side effects
 Cost of medication, copayment, or both
 Barriers to medical care or medications
 Inadequate follow-up or discharge planning
 Missed appointments
Source: Osterberg (2005)25, Kreuger (2005)33, Borzecki (2005)34
Grant et al. (2003) conducted a study evaluating adherence with diabetes-related
medications (including medications for hypertension and hyperlipidemia) in patients with
type 2 diabetes. Overall, patients self-reported high adherence to prescribed medication
regimens; among the patients who were classified as poorly adherent, most were highly
adherent to all but one medication in their regimen. Telephone interviews with patients
found two significant predictors of medication nonadherence: medication adverse effects
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and a lack of patient confidence in the ability of the medication to improve current or
future health.35
Prescription drug cost sharing has been shown to have a negative impact on
medication adherence and treatment duration in multiple chronic conditions. Drug cost
sharing is intended to offset increasing pharmaceutical costs by reducing “discretionary”
pharmaceutical use or steering patients to less-expensive alternatives. However, studies
have shown that cost-sharing techniques, such as co-payments, tiering, pharmacy benefit
“caps”, and formulary restrictions, increase medical services and consequently treatment
costs in diabetic patients.36-38
Alternatively, reducing or removing co-payments has shown positive effects on
medication adherence and health services utilization. Three years after a Pitney Bowes
pharmacy benefit design change – which reduced the cost share of brand name diabetic
medications (25-50% co-payment) to the same 10% co-payment as generic medications –
patients demonstrated significant improvements in medication adherence to both oral
antidiabetic agents and insulin. A 7% decrease in total pharmacy costs was seen,
emergency room visits decreased by 26%, and short-term disability days were reduced by
approximately 50%.37
Another reason for nonadherence in type 2 diabetics is “psychological insulin
resistance,” or the reluctance or refusal of patients to start insulin therapy once insulin is
prescribed. Recent studies suggest that approximately 1 in 4 patients prescribed insulin
therapy initially refuse the treatment, and the remainder express some degree of
unwillingness to initiate insulin therapy.39,40
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Many believe patients are solely responsible for taking their medication and
overlook other important factors which affect one’s behavior and ability to adhere to
treatment. The World Health Organization has categorized the many factors related to
adherence into the following five “dimensions”:
1) Patient-related factors
 Resources, knowledge, attitudes, beliefs, perceptions, and expectations of
the patient
2) Condition-related factors
 Severity of disease, rate of disease progression, co-morbid conditions
3) Therapy-related factors
 Regimen complexity, duration of treatment, adverse effects
4) Health care team and system-related factors
 Patient-provider relationship, health insurance reimbursement, knowledge
and training of health care providers
5) Social/economic factors
 Socioeconomic status, literacy, education level, social support network,
cultural beliefs about illness and treatment
Measuring Medication Adherence
Although medication adherence research is not a new concept, lack of a standard
valid method to measure adherence has been an obstacle in this field of study. Multiple
methods are available to measure patient medication-taking behavior (Table 1.6).
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Table 1.6. Methods of Measuring Adherence
Test Advantages Disadvantages
Direct Methods
Directly observed therapy Most accurate Patients can hide pills in the mouth and
then discard them; impractical for
routine use
Measurement of the level of
medicine or metabolite in
blood
Objective Variations in metabolism and "white-
coat adherence" can give a false
impression of adherence; expensive
Measurement of the biologic
marker in blood
Objective; in clinical trials, can
also be used to measure
placebo
Requires expensive quantitative assays




Simple; inexpensive; the most
useful method in the clinical
setting
Susceptible to error with increases in
time between visits; results are easily
distorted by the patient
Pill counts Objective, quantifiable, and easy
to perform
Data easily altered by the patient
(e.g. pill dumping)
Rates of prescription refills Objective; easy to obtain data A prescription refill is not equivalent to
ingestion of medication; requires a
closed pharmacy system
Assessment of the patient's
clinical response
Simple; generally easy to
perform
Factors other than medication adherence
can affect clinical response
Electronic medication monitors Precise; results are easily
quantified; tracks patterns of
taking medication
Expensive; requires return visits and
downloading data from medication
vials
Measurement of physiologic
markers (e.g. heart rate in
patients using beta-blockers)
Often easy to perform Marker may be absent for other reasons
(e.g. increased metabolism, poor
absorption, lack of response)
Patient diaries Help to correct for poor recall Easily altered by patient
When the patient is a child,
questionnaire for caregiver
or teacher
Simple; objective Susceptible to distortion
Source: Osterberg (2005)25
Direct measurement methods, which include direct observation therapy (DOT)
and blood draws, are difficult (if not impossible) to implement, particularly when
attempting to study adherence in a “real world” setting. Indirect measurement methods,
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which include tablet counts, interviews, diaries, medication event monitoring systems
(MEMS), and review of pharmacy administrative claims, are less accurate, but are more
commonly used for practical reasons. Pharmacy claims are the most frequently used
because such claims are convenient, noninvasive, objective, and inexpensive to obtain.41
Multiple methods of calculating adherence are available using pharmacy claims;
however, the large number methods lead to further complexity in this field of research.
In 2006, Hess et al. published a study on use of pharmacy claims to measure medication
adherence. This study found that between the years 1990 and 2006, eleven different
methods were used to calculate adherence in the literature: continuous measure of
medication adherence (CMA), continuous measure of medication gaps (CMG),
continuous multiple interval measure of oversupply (CMOS), compliance ratio (CR),
continuous, single interval measure of medication acquisition (CSA), days between fills
adherence rate (DBR), medication possession ratio (MPR), medication possession ratio,
modified (MPRm), medication refill adherence (MRA), proportion of days covered
(PDC), and refill compliance rate (RCR).41
The Hess study used data from the LOSE weight (Long-term Outcomes of
Sibutramine Effectiveness on Weight) study to compare these eleven methods and found
that four methods – CMA, CMOS, MPR, and MRA – produced the same results; patients
were 63.5% adherent with their medications (Table 1.7). CMG and PDC methods
produced nearly identical results, showing that patients were 63.0% adherent.41
Measure Formula Value Result (SD)
CMA cumulative days' supply of medication obtainedtotal days to next fill or to end of observation period
adherence value for cumulative time
period 0.635 (0.29)
CMG total days of treatment gapstotal days to next fill or end of observation period
nonadherence value for cumulative
period, winsorized at zero 0.630 (0.28)
CMOS total days of treatment gaps (+) or surplus
a (-)
total days in observation period
nonadherence value for cumulative
period, allowing for surplus 0.635 (0.29)
CR total days supplied - last days' supplylast claim date - first claim date adherence value for period between fills 84.4% (0.22)
b
CSA days' supply obtained at beginning of intervaldays in interval
adherence value for interval of study
participation 1.097 (1.73)
DBR last claim date - first claim date - total days' supplylast claim date - first claim date overall adherence percentage 104.8% (38.6)
MPR days' supply : days in period ratio of medication available 0.635:1 (0.29)
MPRm total days’ supplylast claim date - first claim date + last days' supply
adherence percentage, adjusted to include
final refill period 86.6% (16.6)
MRA total days' supplytotal number of days evaluated overall adherence percentage 63.5% (29.1)
PDC total days’ supplytotal number of days evaluated
RCR (sum of quantity dispensed over interval / quantity tonumber of days in interval between first a
Source: Hess (2006)41
CMA = continuous measure of medication adherence; CMG = continuou
CR = compliance ratio; CSA = continuous, single interval measure of me
ratio; MPRm = medication possession ratio, modified; MRA = medicatio
aSurplus due to early refill or overfill, resulting in excess medication for






Table 1.7 Measures to Calculate Adherence Using Pharmacy Claims23
percentage of days with medication
available 63.0% (28.3)
be taken per day) x 100
nd last refill overall adherence percentage 104.8% (38.6)
s measure of medication gaps; CMOS = continuous multiple interval measur e of oversupply;
dication acquisition; DBR = days between fills adherence rate; MPR = medication possession
n refill adherence; PDC = proportion of days covered; RCR = refill compliance rate






In chronic conditions such as diabetes, increasing medication use has resulted in
demonstrable improvements in health outcomes, reduced hospitalization rates, and
decreased direct health care costs.42-44 However, considering multiple causes of
nonadherence exist, it is not surprising no “one size fits all” solution is available to
improve medication adherence in all patients.
Even in the earliest stages of medication adherence research Sczupak and Conrad
(1977) and Hawkins et al. (1979) demonstrated improved medication adherence,
decreased symptoms, improved kept appointment rates, lower dropout rates, and
decreased hospital admissions when a pharmacist provided care to diabetic patients.45,46
More recently, Roter et al. (1998) conducted a meta-analysis of interventions to improve
medication adherence for all disease states and found that multi-focused interventions
which include cognitive, behavioral, and affective components demonstrate better
outcomes than interventions which focus only on one construct.47
A recently published Cochrane review included 21 studies evaluating
interventions to improve type 2 diabetics’ adherence to treatment recommendations
(excluding diet and exercise recommendations) in outpatient, community, hospital, and
primary care settings.22 Multiple intervention types were evaluated, including diabetes
education, home aids, and nurse-led and pharmacist-led interventions. Although the
majority of interventions showed some improvement in A1Cs, mixed results were seen
among the studies. For example, in one pharmacist-led intervention study, both the
intervention and control groups had a significant improvement in A1C, and the
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intervention group demonstrated significant decreases in body weight and systolic blood
pressure.48 In a second pharmacist-led study, both the intervention and control groups
demonstrated a small increase in self-reported medication adherence, but neither group
had a significant change in A1C.49 The authors concluded that the effectiveness of
medication adherence interventions remains uncertain, as the review of the literature did
not show the interventions to be particularly beneficial or harmful.22
Lu et al. (2008) conducted a more-recent review of the literature specifically
evaluating medication adherence interventions in a managed care setting (N = 51) and
concluded that the following interventions were effective: one-to-one academic detailing,
computerized alerts and reminders, pharmaceutical collaborative care, and multifaceted
disease management. The study also found formulary changes and increases in co-
payments were associated with reduced medication use.50
Diabetes Management Methods
Treatment of diabetes with medication and lifestyle modification is documented
to reduce the risks of diabetic complications. In 2000, the UK Prospective Diabetes
Study (UKPDS) showed that for every 1-point improvement in hemoglobin A1C in type
2 diabetics, the risk of microvascular complications is reduced by 37%, the risk of
myocardial infarction decreases 14%, and the risk of premature death decreases by
21%.51 Similarly, the Diabetes Control and Complications Trial (DCCT) showed that
maintaining blood glucose serum concentrations as close to normal physiologic values as
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possible substantially slowed the onset and progression of eye, nerve, kidney, and heart
disease in Type 1 diabetics.52
Therapeutic Lifestyle Changes
Lifestyle changes are an important first step in treating patients with type 2
diabetes in order to reduce the risk of microvascular and macrovascular complications.
When signs and symptoms are mild, diet and exercise alone can correct glucose
intolerance. Patients with A1C ≤7% at the time of diagnosis are generally initiated on
therapeutic lifestyle changes alone.5 Therapeutic lifestyle changes have been shown to
improve A1C measures by 1-2%.53
Obesity (>120% ideal body weight) is associated with insulin resistance;
therefore, overweight or obese type 2 diabetics are strongly encouraged to lose weight. A
moderate 5% reduction in body weight has been shown to decrease insulin resistance,
improve fasting blood glucose levels, improve serum lipid concentrations, and reduce
blood pressure.54 The combination of a reduced-calorie diet, physical activity, and
behavior therapy aimed at developing skills to change problematic eating and activity
patterns has the greatest potential for helping individuals achieve and maintain long-term
weight goals.1,54
The ADA recommends a minimum of 150 minutes per week of moderate-
intensity physical activity, defined as 50-70% of maximum heart rate, for people with
both type 1 and type 2 diabetes.14 Nutritionally, trans unsaturated fat should be
minimized, saturated fat should comprise <7% of total calories, alcohol consumption
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should be limited to a moderate amount (maximum of 1 drink per day for women and 2
drinks per day for men), and carbohydrates should be carefully monitored via
carbohydrate counting, exchanges, or experience-based estimation.14
Pharmacologic Treatment
Some patients with type 2 diabetes can control and maintain glycemic control
with a healthy diet, exercise, and weight loss, while others may also need oral
prescription medications and/or insulin. Whether or not prescription antidiabetic
medications are needed depends on the individual patient, and this need often changes
over the course of the disease. The severity of metabolic abnormality in a patient can
progress, regress, or remain stable over time.4 However, most patients will require more
than one medication to achieve and maintain glycemic control as the disease progresses.53
In contrast, all patients with type 1 diabetes have an absolute insulin deficiency and
require exogenous insulin to survive.
According to the CDC, 16% of all diabetic adults manage blood glucose with diet
and exercise only, 57% use oral medications only, 13% use oral medications and insulin,
and 14% use insulin only.13 An overview of prescription antidiabetic medication classes
is presented in Table 1.8.
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Table 1.8 Comparative Pharmacology of Antidiabetic Agents
Drug Class Mechanism of Action Generic Names Efficacy Adverse Effects Comments
α-Glycosidase
inhibitors
Slows absorption of complex
carbohydrates
Acarbose, Miglitol ↓ A1C 0.5-1.0%
↓ FPG 20-30 mg/dL
↓ PPG 25-50 mg/dL
Flatulence, diarrhea. LFT
elevation seen with
acarbose – monitor LFTs
Titrate dose slowly to minimize GI
effects. No hypoglycemia or weight
gain. Sucrose inhibits absorption. Use
glycose tablets to treat hypoglycemic
episodes.
Amylin agonists Inhibits glucoagon in a glucose-
dependent manner
Pramlintide ↓ A1C 0.5-1.0% Nausea, vomiting, diarrhea May worsen insulin-induced
hypoglycemia.
Biguanides Enhances insulin sensitivity.
Decreases hepatic glucose output
and increases peripheral glucose
uptake
Metformin ↓ A1C 1.5-1.7%
↓ FPG 50-70 mg/dL






Titrate dose slowly to minimize GI
effects. No hypoglycemia or weight
gain; weight loss possible. Do not use
in patients with renal or hepatic




Stimulates insulin secretion Sitagliptin ↓ A1C 0.6-0.85% Generally well tolerated.
Weight neutral.
Low risk of hypoglycemia. Serious
allergic reactions have been reported
during post-marketing surveillance.
Incretin mimetic Stimulates insulin secretion Exenatide ↓ A1C 0.8-1.0% Weight loss, nausea,
vomiting, diarrhea.
Low risk of hypoglycemia and
favorable effect on weight.





↓ A1C 4%        






Offers flexible dosing to match
lifestyle and glucose concentrations.
Rapid onset. Safe in pregnancy, renal
failure, and liver dysfunction. Drug of





Stimulates insulin secretion Repaglinide,
Netaglinide
↓ A1C 1.7%              
↓ FPG 61 mg/dL       
↓ PPG 48 mg/dL
Hypoglycemia, weight gain Take only with meals. If a meal is
skipped, skip a dose. Flexible dosing
with lifestyle. Safe in renal and liver
failure. Rapid onset.
Sulfonylureas Stimulates insulin secretion. May
decrease hepatic glucose output









↓ FPG 50-70 mg/dL
↓ PPG 92 mg/dL
Hypoglycemia, especially
long-acting agents; weight




Hyperinsulinemia, which leads to
hypoglycemia and weight gain. Some
can be dosed once daily. Rapid onset




Decreases insulin resistance in
muscle and liver, enhancing





↓ FPG 40-55 mg/dL
Weight gain. Rare:
hepatotoxicity
Monitoring of liver function tests is
recommended at baseline, every 2
months for the first year of therapy,
and periodically thereafter.
Source: Koda-Kimble (2005)1, Nathan (2009)53, Doupis (2008)55, Bosi (2008)56, VanDeKoppel (2008)57, Bartels (2007)58
A1C = glycosylated hemoglobin A1C; FPG = fasting plasma glucose; PPG = postprandial glucose; LFT = liver function test; TID = three times daily; GI = gastrointestinal; TG = tryglyceride;
TC = total cholesterol; HDL = high-density lipoprotein cholesterol; CHF = chronic heart failure
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To date, insufficient data are available to support a recommendation of one class
of antidiabetic agent, or combination of agents, over others with regard to long-term
effects and resulting complications.53 The risk of complications appears to be better
predicted by the level of glycemic control achieved rather than any specific medication(s)
used. Therefore, ADA and European Association for the Study of Diabetes (EASD)
consensus guidelines recommend agents primarily based on ability to decrease and
maintain A1C levels; safety, tolerability, ease of use, and cost should also be
considered.53 The treatment algorithm based on this data is presented in Figure 1.3.
Figure 1.3 Diabetes Treatment Algorithm for Type 2 Diabetic Patients
Source: Nathan (2009)53
Well-validated therapies are those that are the best established, most effective, and most cost-effective
therapies for achieving target glycemic goals. This is the preferred route of therapy for most patients.
Less well-validated therapies may be preferred in certain circumstances, such as when hypoglycemia is a




























Advancement from one step to the next in the treatment algorithm should be
based on glycemic control. Patients should have A1C tested every three months until the
individual A1C goal is reached (<7% for most patients), at which time the A1C should be
rechecked at least every six months. The current therapy should be changed (i.e. dose
increased or another agent added) if the A1C is higher than the specific individual goal.
The ADA has the following recommendations for insulin therapy in patients with
type 1 diabetes:14
 Intensive insulin therapy, either via an insulin pump or 3-4 injections per day
of basal and prandial insulin
 Dosing prandial insulin based on premeal blood glucose, carbohydrate intake,
and anticipated activity
 Use of insulin analogs, particularly in patients who commonly experience
hypoglycemia
Disease Management Programs
A growing body of evidence exists indicating that diabetes care provided by a
pharmacist is effective in lowering patient A1C levels to goal.59 The first well-known
study of this type, The Asheville Project, began in 1997 and involved pharmacists who
provided patient education and monitoring in community pharmacies in Asheville, North
Carolina. This intervention showed demonstrable reductions in A1C, the percent of
patients with A1C >9%, mean LDL cholesterol, and the percent of patients with LDL
<100 mg/dL.60 Five years after the study began, the Asheville program showed the
31
ability to maintain patients at lower A1C levels and decrease direct medical costs by
58%.61 The significant clinical and economic outcomes demonstrated in this study
generated a new health care model for patients with diabetes and other chronic
conditions. For example, the American Pharmacists Association (APhA) Foundation’s
Patient Self-Management Program for Diabetes, sometime referred to as the Diabetes Ten
City Challenge, implemented similar pharmacist services in multiple geographic
locations and demonstrated the following outcomes: decrease in mean A1C (7.9% to
7.1%), decrease in mean LDL cholesterol (113.4 mg/dL to 104.5 mg/dL), decrease in
mean systolic blood pressure (136.2 mmHg to 131.4 mmHg), increased annual influenza
vaccinations (52% to 77%), increased annual eye examinations (46% to 82%), and
increased annual foot examinations (38% to 80%), improved satisfaction with overall
diabetes care, and decreased mean health care costs.62 A major limitation of both studies,
however, is that there was no control group for comparison. Therefore, additional studies
were needed to show that the results could be duplicated.
In April 2008, Wubben and Vivian published a review article on the effects of
pharmacist outpatient interventions on adults with diabetes. The review included all
randomized control trials, controlled clinical trials, and cohort studies published through
August 2007; the studies all included a control group and measured outcomes before and
after implementation of the intervention.63 The authors searched multiple databases,
using the following MeSH terms: diabetes mellitus, pharmacy services, pharmacist(s),
NIDDM, and IDDM. A total of 21 articles met the inclusion criteria for the review. A
similar search was conducted for this study using the same search terms to find any
32
additional published articles between September 2007 and April 2009. One additional
study met the inclusion and exclusion criteria for the review, providing a total of 22
separate trials.
Twenty of the 22 studies evaluating the impact of pharmacist activities in an
outpatient diabetes setting used A1C as the primary outcome, with A1C change levels
ranging from an increase of 0.2% to a decrease of 2.1%.63 Interventions which allowed
pharmacists to make medication adjustments reported greater improvements in A1C than
interventions in which pharmacists provided only drug review and disease education.63
Twelve studies measured blood pressure as a secondary outcome, and eleven evaluations
measured cholesterol serum concentrations. Most studies found decreases in blood
pressure and cholesterol serum concentrations in the intervention patients but did not find
significant differences between the intervention and control groups for these variables.63
Purpose
Although multiple medication adherence studies have been performed in diabetic
patients using pharmacy claims data, to date no studies were found to have evaluated the
impact of a pharmacist intervention on diabetic medication adherence. Therefore, the
aim of this investigation was to analyze the impact of a pharmacist-led medication
management program on medication adherence and pharmacy costs and to evaluate




1) To evaluate the impact of a pharmacist-led medication management program on
adherence to and persistence with medications for diabetes, hypertension, and
hyperlipidemia using pharmacy claims data
2) To assess the clinical impact of the intervention on measurements of A1C, blood
pressure, and cholesterol
3) To determine the cost of medications for diabetes, hypertension, and hyperlipidemia
for the patient and health plan
4) To compare adherence to medications for diabetes (co-payment waiver) vs. adherence
to medications for hypertension and hyperlipidemia (no co-payment waiver)
Hypotheses
The following hypotheses were tested in the null form:
H01: There is no relationship between the change in A1C from baseline to follow-up for
patients participating in the medication management program and patients receiving
usual care.
H02: There is no relationship between the change in the percentage of patients achieving
goal A1C (<7%) from baseline to follow-up for patients participating in the
medication management program and patients receiving usual care.
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H03: There is no relationship between the change in the percentage of patients with poor
glycemic control (A1C >9%) from baseline to follow-up for patients participating in
the medication management program and patients receiving usual care.
H04: There is no relationship between the change in the percentage of patients achieving
goal blood pressure (BP <130/80) from baseline to follow-up for patients
participating in the medication management program and patients receiving usual
care.
H05: There is no relationship between the change in the percentage of patients achieving
all goal cholesterol levels (LDL <100, HDL >40 for males, HDL >50 for females,
total cholesterol <200, triglycerides <150) from baseline to follow-up for patients
participating in the medication management program and patients receiving usual
care.
H06: There is no relationship between the change in adherence to medications for
diabetes from baseline to follow-up for patients participating in the medication
management program and patients receiving usual care.
H07: There is no relationship between the change in adherence to medications for
hypertension from baseline to follow-up for patients participating in the medication
management program and patients receiving usual care.
H08: There is no relationship between the change in adherence to medications for
hyperlipidemia from baseline to follow-up for patients participating in the
medication management program and patients receiving usual care.
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H09: There is no relationship between the change in patient pharmacy costs for
diabetes/hypertension/hyperlipidemia/other medications and testing supplies for
patients participating in the medication management program and patients
receiving usual care.
H010: There is no relationship between the change in health plan pharmacy costs for
diabetes/hypertension/hyperlipidemia/other medications and testing supplies for
patients participating in the medication management program and patients
receiving usual care.
H011: There is no relationship between the ability of patients to achieve goal A1C
(<7%) and study group, sex, age, diabetes type, improvement in medication
adherence, improvement in medication persistence, initiation of insulin therapy,
increased number of antidiabetic agents, or increased use of diabetic testing
supplies.
Study Design
This study was a quasi-experimental, longitudinal, pre-post study, with a control
group. Patients were drawn from the Scott and White Health Plan (SWHP)
membership database. SWHP is a staff-model, non-profit, managed care organization
with over 200,000 members and includes 4 hospitals, 7 retail pharmacies, and more
than 20 local and regional clinics in central Texas. The pharmacist intervention took
place in four of the retail pharmacies. Patients who met the inclusion criteria and lived
“nearby” (within 30 miles of the four participating pharmacies) were invited to
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participate in the intervention, while those who were not defined as living “nearby”
served as control patients.
A “rolling” enrollment period from August 2006-July 2008 was utilized. Data for
one year prior to study enrollment were collected to determine subject baseline, and each
subject was followed for one year after study enrollment. Therefore, data were collected
from August 2005-July 2009 (Figure 2.1). The “study enrollment date” for control
patients was based on the enrollment date of that subject’s matched intervention
counterpart.
Patients were analyzed on an intent-to-treat basis. Resources used to identify and
follow patients included the SWHP membership database, clinic and hospital electronic
medical records, and SWHP prescription and medical claims.
Figure 2.1. Study Time Frame






The intervention group was identified prospectively, while the control group was
identified at the time of analysis. Intervention and control patients were matched on age
and sex.
Inclusion Criteria
Potential subjects were members of SWHP and were identified from SWHP
claims data. To be included in the study, subjects must have been between the ages of 18
and 63 at the time of study enrollment and continuously enrolled in SWHP for the two-
year data collection period. Subjects must have had a formal diagnosis of diabetes, as
specified by HEDIS, which includes the ICD-9 codes 250.xx, 357.2x, 362.0x, and
366.41. To target patients at high risk for poor outcomes, the most recent A1C
measurement for each subject must have been > 7.5%. The control patients were
required to meet the same inclusion criteria but were not invited to participate in the
program due to the geographic constraints noted above.
Exclusion Criteria
Patients were not enrolled in the study if their physician declined to enroll the
patient in the program, if the patient declined to give informed consent, or if the patient
had impaired ability to comprehend or converse in English (i.e. mentally disabled,
advanced dementia, non-English speaking). In addition, subjects were excluded if they
currently or formerly participated in the institution’s medication management clinic
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(MMC), a similar pharmacist-led medication management program for poorly controlled
diabetic patients, during the previous 90 days. Two main differences existed between the
medication management program studied in this evaluation and the MMC. The first
difference was that patients in the MMC were referred by their physicians because those
patients were difficult to control, whereas patients in the medication management
program were invited to the program based on most recent A1C levels and geographic
location. The second difference between the programs was that patients in the
medication management program spent approximately 20 minutes during each pharmacy
visit learning about a predetermined diabetes-related topic; this formal education was not
provided in the MMC.
Recruitment Procedure
SWHP medical claims, medical records, and enrollment data were screened for
patients meeting the aforementioned inclusion and exclusion criteria. An introductory
letter with a list of patients meeting criteria for participation in the medication
management program was sent to the prescribing physician in charge of their diabetes
care (Appendix I). The physician was asked to indicate appropriateness for program
participation for each patient and to return the list to the SWHP pharmacy. The letter to
the physician also indicated that patients enrolled in the program would be eligible to
participate in the study protocol.
All patients identified as potential intervention group participants and approved
by their physician were contacted by mail with an introductory letter explaining the
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program and study protocol (Appendices II and III). The mailing informed patients that
they would be contacted within 10 days to discuss possible participation in the program
and the research study. The mailing included a self-addressed, stamped envelope and a
card on which to indicate willingness to participate in the program. Patients returning the
card declining participation in the program were not contacted. Pharmacy telephone
numbers were provided in the introductory letter to provide patients who had questions
access to information.
Study participants were asked to sign an Authorization for Use and Disclosure of
Health Information for Research Purposes that was blended with the Consent Form prior
to participating in the research study (Appendix IV). Written informed consent was
obtained in person for each participant prior to the initial pharmacy appointment.
SWHP medical claims, medical records, and enrollment data were collected and
analyzed retrospectively for patients in the control group. A waiver of informed consent
was granted for control patients because information for those individuals was already
collected for non-research purposes, as the data came from documentation of their usual
care. Institutional Review Board approval for the study was obtained from Scott &
White Health System and The University of Texas at Austin.
Matching Procedure
To match intervention and control patients, random numbers were assigned to
each potential control patient. The control patient with the lowest number matching an
intervention patient on sex and age was selected as the intervention patient’s matched
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control. In the event no control patient was found that matched an intervention patient
for sex and age, the control patient of the same sex whose date of birth was closest to the
intervention patient’s date of birth was included.
Intervention
Patients in the intervention group met monthly with a SWHP pharmacist in a
private patient counseling office in one of the four participating SWHP retail pharmacies.
At the initial 60-minute appointment, the pharmacist evaluated the patient therapy needs
and developed a patient care plan, with the goal of achieving an A1C <7%, unless
otherwise specified, per ADA recommendations. During each 30-minute follow-up
appointment, the pharmacist spent approximately 20 minutes teaching the patient about
different diabetes-related topics, such as appropriate use of a glucometer, the importance
of foot care, how to read nutrition labels, and the importance of exercise (Table 2.1). A
complete list of educational topics discussed and the sources from which those topics
were derived is available in Appendix V.
In addition, the pharmacist monitored the patient as recommended by the ADA,
evaluated home blood glucose journals, and made medication adjustments when
necessary as allowed under a collaborative practice agreement with physicians (Appendix
VI). While flexibility existed in the program to address specific areas of concern for each
patient at each visit, a general listing of all scheduled procedures for each appointment is
presented in Table 2.2.
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Table 2.1 Schedule of Intervention Educational Topics
Visit # Educational Topic
1 Overview and goals of therapy
2 Self-monitoring blood glucose / how to use a glucometer
3 Acute complications
4 Medication timing and administration
5 Nutrition requirements / reading nutrition labels
6 Carbohydrate counting
7 Exercise





Table 2.2. Scheduled Procedures at Each Medication Management Program Visit
Visit Number
Scheduled Procedures 1 2 3 4 5 6 7 8 9 10 11 12
Patient history (medical, social, family) X
Medications X X X X X X X X X X X X
Self-monitored blood glucose (SMBG) readings X X X X X X X X X X X X
Diet and exercise X X X X X X X X X X X X
Preventative health X
Physical assessment* X X X X X X X X X X X X
Labs
Hemoglobin A1C X X X X X
Glucose X X X
Lipids X X X
Liver function tests X X X
Thyroid stimulationg hormone (TSH) X X
Potassium X X
Creatinine X X
Blood urea nitrogen (BUN) X X
Urine microalbumin X X
*includes weight, blood pressure, pulse, and visual foot exam; a comprehensive foot exam with monofilament test
will be performed if one has not been documented in the medical record within the previous 12 months
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In addition to the monthly care provided by a pharmacist, diabetic medications
and testing supplies were provided free to patients participating in the intervention.
Patients were provided with, and asked to sign, a SWHP insurance contract waiver
specifying the terms under which prescription co-payments were to be waived as well as
the list of approved medication and supplies at the first medication management program
appointment (Appendix VII).
Outcome Measures
Clinical Measures: A1C, Blood Pressure, Cholesterol
The clinical measures in this analysis were the absolute change in A1C, blood
pressure, total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C),
and triglycerides (TG). The percentage of patients achieving goal levels for diabetes
(A1C <7%), hypertension (BP <130/80), and hyperlipidemia (TC <200, LDL-C <100,
HDL-C ≥60, TG <150) at baseline and follow-up were calculated. In addition, the
percentage of patients with an uncontrolled A1C, defined by HEDIS as A1C >9%, was
calculated and compared between intervention and control groups.64
Data were obtained from the electronic medical record. The most recent
measurement prior to study enrollment and the one-year follow-up appointment was used
for baseline and follow-up measures, respectively. To attain the most accurate baseline
and follow-up measurements, in the event a recent clinical measurement was not
available prior to the study enrollment and follow-up dates, a measurement obtained
within a 30 day grace period of these dates was used in place of the older measurement.
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One exception to this rule occurred in the determination of baseline glycemic control.
Since the A1C test is a time-weighted average of mean daily blood glucose which places
the greatest weight on current glucose levels, a 10-day grace period was established for
baseline A1C measurements.
Adherence Measures: Medication Adherence and Persistence
This evaluation applied the most commonly used method to estimate patient
adherence using retrospective databases – the medication possession ratio (MPR). With
this method, medication adherence rates for individual patients are reported as the
percentage of the prescribed doses of the medication taken by the patient over a specified
period. The formula to calculate MPR was as follows:
Total Days’ Supply of Medication within the Refill Interval
Number of Days in the Refill Interval
where the refill interval was defined as:
 days between index date (first fill in the baseline period), and baseline end
(study enrollment date -1), for the baseline MPR
 days between index date (first fill in the follow-up period) and study end
(study enrollment date +364), for the follow-up MPR
and the total days’ supply of medication was defined as:
 the sum of days’ supply for all prescriptions filled within the refill interval
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If the date of the last refill in the refill interval extended by the days’ supply of the last
refill was greater than the baseline/study end date, the days’ supply was truncated at the
baseline/study end date. An example of the MPR calculation is presented in Figure 2.2.
*The days’ supply was excluded from the follow-up MPR calculation because this medication was filled during the
baseline period. Similarly, the days’ supply for any medication filled prior to the baseline period would not be included
in the baseline MPR calculation.
Medication names, days’ supply of medication, and medication fill dates were
obtained from SWHP pharmacy claims. MPRs were calculated for each unique
medication class filled by a patient at least twice during the baseline/follow-up period.
Two medication fills were required to help ensure adherence calculations included only





Figure 2.2. Illustration of Medication Possession Ratio Calculation Terms
Baseline Period Follow-up Period
Day -365 to Day -1 Day 0 to Day 364
12 months




Days’ Supply Included in Calculation Days’ Supply Excluded from Calculation*
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For patients taking more than one medication class for a particular condition (i.e.
a beta blocker and diuretic for hypertension), or combination products (i.e. valsartan/
hydrochlorothiazide), MPRs for each unique medication class were calculated; the
medication class MPRs were averaged to generate one overall MPR for that condition.
Therefore, up to three distinct MPRs were calculated for each individual subject in order
to determine (1) adherence to medications for diabetes (oral medications and exenatide),
(2) adherence to medications for hypertension, and (3) adherence to medications for
hyperlipidemia. A complete list of all medications used in the MPR calculations and the
classification of each medication is presented in Appendix VIII.
Adherence to insulin was not calculated as it is difficult to ascertain whether
patients were taking doses as prescribed, particularly since insulin doses may be
prescribed on a sliding scale and because insulin should be discarded 28 days after a vial
is opened. On the other hand, adherence to the injection medication exenatide was
included in adherence calculations since this agent has a fixed-dose, twice-daily
administration schedule.
Medication possession ratios can range from 0% to 100%. In this study, MPRs
ranged from 17% to 100%. Patients were considered adherent if their MPR was greater
than or equal to 80%.
Medication persistence was calculated as the number of days that a patient
remained on therapy during the baseline and follow-up periods. Up to three medication
regimens were identified for each patient, to measure persistence with medications for (1)
diabetes, (2) hypertension, and (3) hyperlipidemia. The medication regimens consisted of
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all medications first filled within the first 120 days of the baseline or follow-up periods.
Only one fill of a medication was required to be included in the persistence calculation,
as the purpose of calculating persistence is to determine the length of time a patient
remains on a prescribed medication regimen.
A medication was considered discontinued if the agent was not refilled within 30
days of the last fill date extended by the days’ supply of the last fill. As with the MPR
calculations, persistence calculations could include more than one medication and/or
combination medications for a particular condition, and insulin therapy was not included
in the calculations. The formula to calculate days of persistence was as follows:
Date of Discontinuation – Date of First Medication Fill
where the date of discontinuation was defined as:
 the date prior to a 30-day gap in therapy
and date of first medication fill was defined as:
 the first date a medication was filled
If patients took more than one medication and/or combination medications for a
particular condition, the date of first medication fill was defined as the last first fill date
of a medication in the combination regimen, and the date of discontinuation was defined
as the first date of discontinuation of any agent in the combination regimen (Figures 2.3-
2.4). In addition, the percentage of patients remaining on therapy at 6 months was







-12 months 12 months
Figure 2.3. Baseline Persistence Measurement Example
120 Days
Baseline persistence calculated for medications
filled during the first 120 days (except insulin)
End of baseline period
(study enrollment date -1)









Follow-up persistence calculated for medications
filled during the first 120 days (except insulin)
120
-12 months 12 months
Glyburide not measured
(no fills in first 120 days)
Figure 2.4. Follow-up Persistence Measurement Example
30 Day
Metformin discontinued
(not refilled within 30 days)
Days on Therapy
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Economic Measures: Patient and Health Plan Pharmacy Costs
Pharmacy costs for both the patient and health plan were obtained from SWHP
pharmacy claims data. Costs were divided into the following categories: medications and
testing supplies for diabetes, medications for hypertension, medications for
hyperlipidemia, and total medication and testing supply costs. Patient medication costs
included both deductibles and co-payments for each medication. Pharmacy costs were
adjusted to 2009 dollars using the consumer price index for medical commodities.


































Source: United States Department of Labor: Bureau of Labor Statistics65
Note: 2009 CPI estimated from 1999-2008 trendline.
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Data Analysis
Descriptive statistics were used to report clinical measures, medication adherence,
and pharmacy costs. Means and standard deviations were reported for continuous
variables, and frequencies and percents were reported for categorical variables. In
addition, medians were reported for pharmacy costs as the cost data were not normally
distributed.
Chi-square tests were used to analyze baseline co-morbidities in the two groups.
Two-sample paired student’s t-tests were used to analyze the change in A1C, MPR, days
to discontinuation, and pharmacy costs between the groups. Generalized linear modeling
was used to determine if a difference was seen between the groups in the percentage of
patients achieving blood pressure control, cholesterol control, the percentage of patients
adherent (MPR ≥80%) with medications for diabetes, hypertension, and hyperlipidemia,
the percentage of patients with uncontrolled A1C (>9%), and the percentage of patients
remaining on therapy at 6 months. McNemar’s test was used to determine if a difference
was seen in the percentage of patients achieving glycemic control (A1C<7%) instead of
generalized linear modeling because no patients had glycemic control at baseline per the
study inclusion criteria. A multivariate logistic regression was conducted to determine
factors related to the achievement of glycemic control (A1C <7%). An a priori level of
significance was set at 0.05. Data were analyzed using SPSS 16.0 (SPSS Inc., Chicago,




Approximately 12,000 diabetic patients receiving health care from SWHP were
screened for participation in the medication management program. A complete overview
of the patient screening, study enrollment, and matching process for both intervention and
control patients is provided in Figure 3.1. Between August 2006 and July 2008, 171
patients enrolled in the medication management program. Of these, 137 patients enrolled
in the research study evaluating the program. Reasons for participating in the medication
management program but not the research study included unwillingness or inability to
provide informed consent, participation in the Medication Management Clinic (MMC)
within 90 days of program enrollment, and a most recent A1C prior to program
enrollment ≤7.5%. Although patients had been screened for an A1C >7.5% prior to
being invited to participate in the medication management program, some patients had an
additional A1C test result between the time of screening and program enrollment which
was ≤7.5%, therefore, making the patient ineligible for the research study.
Nearly 86% of patients (N = 118) remained in the program for at least one year
and were analyzed in this evaluation. Of the 19 patients who did not remain in the
program, 13 were not continuously enrolled in SWHP, 1 died (chronic heart failure), 4
patients requested to leave the program, and 1 patient was dismissed for not attending the
required monthly appointments with the pharmacist.
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Note: Most numbers are approximations as there was a rolling enrollment process. Inclusion/exclusion criteria variables, such as age,
length of continuous enrollment, and most-recent A1C test results changed over time for each patient. Therefore, the total number of
patients that were eligible/ineligible for the study varied across the duration of the study.







Treated at Temple, Georgetown,





















Most Recent A1C >7.5%
N ~ 548
Most Recent A1C Prior to
Study Enrollment Date >7.5%
N = 247
Continuously Enrolled Two Years
(1 Before & 1 After Study Enrollment Date)
N = 564
1:1 Match with Intervention Patients
N = 118
INTERVENTION CONTROL
Reasons for Exclusion from Study:
4 no study consent
17 enrolled in MMC within past 90 days
11 most recent A1C not >7.5%
2 unable to provide consent
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As intervention and control patients were matched on sex and age, both groups
were 55% female, ranged in age from 28-62 years, and had a mean age of 51.3 years
(intervention group SD = 7.9 years, control group SD = 7.7 years). Although all patients
were required to have diabetes, type of diabetes was not matched. Fourteen patients in
the intervention group and 3 patients in the control group were type 1 diabetics,
respectively. This difference was statistically significant (P<0.05).
Co-morbidities of primary interest included hypertension and hyperlipidemia. In
both groups, 80-84% of patients had hypertension and/or hyperlipidemia. A low
prevalence of diabetes-related complications was seen in both groups; complications
included nephropathy, neuropathy, and retinopathy (Table 3.1). No significant difference
between the groups was seen in the prevalence of co-morbid conditions.
Table 3.1. Prevalence of Diabetes-Related Chronic Conditions in Intervention and Control Patients at Baseline
Condition Intervention Control P-value
Type 1 Diabetes 14 (11.9%) 3 (2.5%) <0.05
Type 2 Diabetes 104 (88.1%) 115 (97.5%) <0.05
Hypertension 99 (83.9%) 98 (83.0%) 1.000
Hyperlipidemia 99 (83.9%) 95 (80.5%) 0.610
Retinopathy 15 (12.7%) 11 (9.3%) 0.679
Nephropathy 6 (5.1%) 3 (2.5%) 0.499
Neuropathy 2 (1.7%) 2 (1.7%) 1.000
Source: Medical chart review for diabetes, hypertension, and hyperlipidemia; ICD-9 codes for other conditions




Patients in the intervention and control groups had similar baseline A1C
measurements (Figure 3.2). At baseline, 45% and 55% of patients in the intervention and
control groups, respectively, had poor glycemic control, as defined by HEDIS guidelines
(A1C >9%).

































P=0.297 for paired t-test
Table 3.2 displays the mean baseline and follow-up A1C measurements for both
groups. The mean change in A1C from baseline to follow-up in the intervention group
was -1.1 ± 1.6, whereas the mean change in the control group was -0.6 ± 1.1. The
difference in A1C change between the groups was statistically significant (P<0.05).
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Table 3.2. Glycemic Control at Baseline and Follow-up in Intervention and Control Patients
INTERVENTION GROUP CONTROL GROUP
N = 118 N = 118
Mean ± SD A1C Significance Level
Baseline 9.3 ± 1.5 9.5 ± 1.5
Follow-up 8.2 ± 1.4 9.0 ± 1.9
Difference -1.1 ± 1.6 -0.6 ± 1.1
P<0.05a
N (%) Patients with Glycemic Control, Defined as A1C <7%
Baseline 0 (0%) 0 (0%)
Follow-up 19 (16.1%) 13 (11.0%)
P=0.345b
N (%) Patients with Uncontrolled Hyperglycemia, Defined as A1C >9%
Baseline 53 (44.9%) 65 (55.1%)
Follow-up 31 (26.3%) 54 (45.8%)
P=0.163c




c. Generalized linear model
Table 3.2 also shows the number and percentage of patients in each group who
achieved the ADA recommended goal of A1C <7% during the one year follow-up. The
difference between the groups in the percentage of patients achieving the A1C goal was
not statistically significant (P=0.345).
The HEDIS definition of poor glycemic control (A1C >9%) was also used to
evaluate the impact of the intervention on glycemic control. Although a greater reduction
in the percentage of patients with poor glycemic control was seen in the intervention
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group (45% at baseline to 26% at follow-up) than the control group (55% at baseline to
46% at follow-up), the difference was not statistically significant (P=0.163).
It should be noted that while all intervention patients had a baseline A1C
measurement and at least one follow-up measurement available to evaluate the change in
A1C over time, 11 control patients did not have a second A1C test result recorded in the
electronic medical record during the one-year follow-up period. In the aforementioned
analyses, the value of the baseline A1C measurement was used for both the baseline and
follow-up in patients without a follow-up measurement.
A second evaluation of glycemic control was performed which excluded patients
(and their individual matched pair) who did not have a follow-up A1C measurement.
The purpose was to ensure that the 11 control patients with no change in A1C from
baseline to follow-up, due to lack of a follow-up measurement, were not adversely
affecting the study results. The results of these analyses, displayed in Table 3.3, support
the prior claims. A significant difference in the absolute reduction of A1C was seen
between the groups, but no significant differences were observed in the percentage of
patients achieving A1C goal of <7% or in the reduction of the percentage of patients with
poor glycemic control.
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Table 3.3. Glycemic Control in Intervention and Control Patients with Both Baseline and Follow-up A1C Results
INTERVENTION GROUP CONTROL GROUP
N = 107 N = 107
Mean ± SD A1C Significance Level
Baseline 9.3 ± 1.5 9.5 ± 1.5
Follow-up 8.2 ± 1.3 8.9 ± 1.9
Difference -1.1 ± 1.5 -0.6 ± 1.8
P<0.05a
N (%) Patients with Glycemic Control, Defined as A1C <7%
Baseline 0 (0%) 0 (0%)
Follow-up 16 (15.0%) 13 (12.1%)
P=0.689b
N (%) Patients with Uncontrolled Hyperglycemia, Defined as A1C
>9%
Baseline 48 (44.9%) 59 (55.1%)





c. Generalized linear model
Interestingly, none of the fourteen intervention patients with type 1 diabetes
achieved glycemic control at the follow-up, and only one of the three control patients
with type 1 diabetes achieved the goal A1C. Based on this finding, an additional analysis
of type 2 diabetics only was conducted (Table 3.4). Similar to the previous results, a
greater decline in A1C was observed in the intervention group compared to the control
group, -1.2% vs. -0.5%, respectively; the difference was statistically significant (P<0.05).
More type 2 diabetics in the intervention group than in the control group achieved goal
58
A1C, but the difference was not statistically significant (P=0.522). Also, no significant
difference was seen between the groups in the reduction of patients with poor glycemic
control (P=0.293).
Table 3.4. Glycemic Control in Type 2 Diabetic Intervention and Control Patients
INTERVENTION GROUP CONTROL GROUP
N = 102 N = 102
Mean ± SD A1C Significance Level
Baseline 9.4 ± 1.6 9.4 ± 1.5
Follow-up 8.2 ± 1.3 9.0 ± 1.8
Difference -1.2 ± 1.6 -0.5 ± 1.8
P<0.05a
N (%) Patients with Glycemic Control, Defined as A1C <7%
Baseline 0 (0%) 0 (0%)
Follow-up 15 (14.7%) 11 (10.8%)
P=0.522b
N (%) Patients with Uncontrolled Hyperglycemia, Defined as A1C >9%
Baseline 34 (33.3%) 42 (41.2%)





c. Generalized linear model
Blood Pressure Control
Table 3.5 displays mean systolic and diastolic blood pressures for intervention
and control patients at baseline and follow-up. Patients were further stratified by a
diagnosis of hypertension, based on manual review of the electronic medical record.
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Table 3.5. Mean Blood Pressure and Percentage of Patients at BP Goal <130/80 mmHg at Baseline and Follow-up By Group and Hypertension Diagnosis
INTERVENTION GROUP CONTROL GROUP
HTN Dx No HTN Dx All Patients HTN Dx No HTN Dx All Patients
N = 99 N = 19 N = 118 N = 98 N = 20 N = 118
Systolic Blood Pressure
Mean ± SD (mmHg)
Baseline 132.0 ± 15.3 120.5 ± 13.4 130.1 ± 15.6 134.9 ± 18.4 128.8 ± 16.7 133.9 ± 18.2
Follow-up 130.3 ± 15.4 120.7 ± 11.9 128.7 ± 15.3 136.0 ± 18.3 126.7 ± 13.4 134.4 ± 17.8
Difference -1.7 ± 18.2 0.2 ± 13.7 -1.4 ± 17.5 1.1 ± 19.2 -2.1 ± 18.8 0.6 ± 19.1
Diastolic Blood Pressure
Mean ± SD (mmHg)
Baseline 74.4 ± 10.8 70.8 ± 8.8 73.8 ± 10.5 73.1 ± 9.2 71.9 ± 9.4 72.9 ± 9.2
Follow-up 73.9 ± 10.1 71.1 ± 9.7 73.5 ± 10.0 73.1 ± 10.5 72.3 ± 10.0 72.9 ± 10.4
Difference -0.5 ± 11.2 0.3 ± 9.9 -0.3 ± 10.9 -0.1 ± 9.0 0.4 ± 10.7 0.0 ± 9.3
N (%) Patients with Blood Pressure at Goal, Defined as BP <130/80 mmHga
Baseline 41 (34.7%) 13 (68.4%) 54 (45.8%) 31 (31.6%) 9 (45.0%) 40 (33.9%)
Follow-up 42 (35.6%) 13 (68.4%) 55 (46.6%) 28 (28.6%) 10 (50.0%) 38 (32.2%)
N (%) Patients with Systolic BP at Goal, Defined as SBP <130 mmHg
Baseline 45 (38.1%) 14 (73.7%) 59 (50.0%) 36 (36.7%) 10 (50.0%) 46 (39.0%)
Follow-up 48 (40.7%) 13 (68.4%) 61 (51.7%) 30 (30.6%) 12 (60.0%) 42 (35.6%)
N (%) Patients with Diastolic BP at Goal, Defined as DBP <80 mmHg
Baseline 67 (56.8%) 17 (89.5%) 84 (71.2%) 73 (74.4%) 16 (80.0%) 89 (75.4%)
Follow-up 71 (60.2%) 16 (84.2%) 87 (73.7%) 75 (76.5%) 16 (80.0%) 91 (77.1%)
HTN = hypertension, Dx = diagnosis, BP = blood pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure
a. Significance test by generalized linear model: P=0.737
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In both the intervention and control group, mean blood pressures of patients
without a diagnosis of hypertension tended to be slightly lower than those with a chart-
documented hypertension diagnosis. Mean systolic and diastolic blood pressures
remained relatively unchanged between baseline and follow-up in both groups, regardless
of whether or not patients had a diagnosis of hypertension.
The percentage of patients meeting the ADA blood pressure goal of BP <130/80
mmHg remained stable over time in both groups, with approximately 46% patients in the
intervention group and 33% of patients in the control group achieving that goal. A
generalized linear model indicated no significant improvement in blood pressure control
in the intervention group compared to the control group (P=0.737).
Further analysis of the systolic and diastolic blood pressures indicated that
uncontrolled systolic blood pressure was largely responsible for the inability of patients
to achieve the overall blood pressure goal of <130/80 mmHg, as the majority (71-77%) of
patients met the diastolic BP goal of <80 mmHg. As with the overall blood pressure goal
results, fewer patients in the control group had controlled systolic blood pressures
compared to the intervention group.
Cholesterol Control
Table 3.6 displays mean HDL cholesterol, LDL cholesterol, total cholesterol, and
triglyceride levels for intervention and control patients at baseline and follow-up. Similar
to the blood pressure analysis, patients were further stratified by a diagnosis of
hyperlipidemia, based on manual review of the electronic medical record. With the
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Table 3.6. Change in Mean Cholesterol Levels From Baseline to One-Year Follow-up in Intervention and Control Patients
INTERVENTION GROUP CONTROL GROUP
HLP Dx No HLP Dx All Patients HLP Dx No HLP Dx All Patients
Cholesterol Test N = 99 N = 19 N = 118 N = 94 N = 20 N = 114
HDL Cholesterol
Mean ± SD (mg/dL)
Baseline 41.0 ± 11.5 49.2 ± 18.3 42.3 ± 13.1 42.8 ± 12.1 42.6 ± 10.0 42.7 ± 11.7
Follow-up 40.0 ± 11.1 47.8 ± 20.4 41.3 ± 13.2 42.9 ± 12.0 43.6 ± 9.9 43.0 ± 11.6
Difference -1.0 ± 6.3 -1.4 ± 7.3 -1.0 ± 6.5 0.0 ± 6.6 1.1 ± 5.3 0.2 ± 6.4
LDL Cholesterol
Mean ± SD (mg/dL)
Baselinea 90.1 ± 36.1 97.4 ± 19.2 91.4 ± 33.9 100.9 ± 40.3 106.5 ± 27.9 102.0 ± 38.1
Follow-upb 83.1 ± 33.4 94.2 ± 25.5 84.9 ± 32.4 96.1 ± 38.6 105.4 ± 34.7 97.9 ± 37.9
Difference -6.0 ± 29.2 -4.6 ± 21.8 -5.7 ± 28.0 -5.0 ± 37.6 -1.1 ± 33.9 -4.2 ± 36.7
Total Cholesterol
Mean ± SD (mg/dL)
Baseline 168.4 ± 45.5 177.3 ± 20.0 169.8 ± 42.5 185.4 ± 52.8 175.2 ± 32.0 183.6 ± 49.8
Follow-up 161.7 ± 47.6 165.9 ± 32.5 162.4 ± 45.4 176.7 ± 51.0 174.0 ± 41.2 176.2 ± 49.2
Difference -6.8 ± 34.9 -11.3 ± 27.9 -7.7 ± 33.8 -9.2 ± 45.2 -1.2 ± 35.9 -7.8 ± 43.7
Triglycerides
Mean ± SD (mg/dL)
Baseline 194.5 ± 143.2 154.0 ± 78.6 188.0 ± 135.5 232.1 ± 187.6 131.2 ± 42.9 214.4 ± 175.4
Follow-up 184.8 ± 110.0 131.6 ± 102.3 176.2 ± 110.1 203.0 ± 192.0 125.1 ± 50.3 189.3 ± 177.9
Difference -9.7 ± 103.4 -22.4 ± 69.6 -11.7 ± 98.6 -29.1 ± 162.3 -6.1 ± 43.0 -25.1 ± 148.5
HLP = hyperlipidemia, Dx = diagnosis
Note: 19 control and 8 intervention patients had no lipid tests during the one-year follow-up.
a. Due to excessively high TG levels, 7 intervention and 13 control patients with a HLP dx had no baseline LDL value.
b. Due to excessively high TG levels, 6 intervention and 8 control patients with a HLP dx had no follow-up LDL value.
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exception of HDL cholesterol in the intervention group, some improvement in all
cholesterol types was seen at the one-year follow-up compared to baseline in both groups,
regardless of whether or not patients carried a hyperlipidemia diagnosis.
Table 3.7 shows the percentage of intervention and control patients who met the
recommended cholesterol levels of HDL cholesterol >40 mg/dL (males), HDL
cholesterol >50 mg/dL (females), LDL cholesterol <100 mg/dL, total cholesterol <200
mg/dL, and triglycerides <150 mg/dL individually, as well as the percentage of patients
who met all four goals at baseline and follow-up. In the intervention group, the
percentage of patients meeting all cholesterol goals stayed relatively unchanged from
baseline (11%) to follow-up (12%), whereas a slightly greater improvement was seen in
the control group (7% to 12%). However, a generalized linear model showed that the
difference was not significant (P=0.268).
Since the primary goal of lipid treatment in diabetic patients is to control LDL
cholesterol levels, a generalized linear model was used to assess the change in LDL
cholesterol control between the intervention and control groups. Both intervention and
control groups showed some improvement in LDL cholesterol control, and no significant
difference was seen between the groups (P=0.925). However, it should be noted that it
was difficult to accurately assess LDL cholesterol control, because LDL levels could not
be calculated for 20 patients at baseline and 14 patients at follow-up due to excessively
high triglyceride levels.
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Table 3.7. Number and Percentage of Intervention and Control Patients Meeting ADA Cholesterol Guidelines at Baseline and Follow-up
HDL Cholesterol LDL Cholesterol Total Cholesterol Triglycerides All Lipid Tests
N (%) Patients at
Goal >40 mg/dL (males) N (%) Patients at N (%) Patients at N (%) Patients at N (%) Patients
Goal >50 mg/dL (females) Goal <100 mg/dL Goal <200 mg/dL Goal <200 mg/dL Meeting All Goal Valuesa
N Baseline Follow-up Baselineb Follow-upc Baseline Follow-up Baseline Follow-up Baseline Follow-up
INTERVENTION
HLP Diagnosis 99 27 (27.3%) 24 (24.2%) 60 (65.2%) 72 (77.4%) 74 (74.4%) 87 (87.9%) 44 (44.4%) 36 (36.4%) 11 (11.1%) 11 (11.1%)
No HLP Diagnosis 19 8 (42.1%) 7 (36.8%) 9 (47.4%) 10 (52.6%) 16 (84.2%) 15 (78.9%) 10 (52.6%) 15 (78.9%) 2 (10.5%) 3 (15.8%)
All Patients 118 35 (29.7%) 31 (26.3%) 69 (62.2%) 82 (73.2%) 90 (76.3%) 102 (86.4%) 54 (45.8%) 51 (43.2%) 13 (11.0%) 14 (11.9%)
CONTROL
HLP Diagnosis 94 30 (31.9%) 30 (31.9%) 40 (49.4%) 52 (64.2%) 61 (64.9%) 64 (68.1%) 37 (39.4%) 42 (44.7%) 5 (5.3%) 11 (11.7%)
No HLP Diagnosis 20 6 (30.0%) 8 (40.0%) 11 (55.0%) 11 (55.0%) 15 (75.0%) 15 (75.0%) 13 (65.0%) 16 (80.0%) 3 (15.0%) 3 (15.0%)
All Patients 114 36 (31.6%) 38 (33.3%) 51 (45.9%) 63 (56.8%) 76 (66.7%) 79 (69.3%) 50 (43.9%) 58 (50.9%) 8 (7.0%) 14 (12.3%)
HLP = hyperlipidemia
Note: 19 control and 8 intervention patients had no lipid tests during the one-year follow-up.
a. Significance test by generalized linear model: P=0.268
b. Due to excessively high TG levels, 7 intervention and 13 control patients with a HLP dx had no baseline LDL value.
c. Due to excessively high TG levels, 6 intervention and 8 control patients with a HLP dx had no follow-up LDL value.
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Among the four lipid types, patients in both the intervention and control groups
were least likely to achieve the HDL cholesterol goal, with only approximately one-third
of patients meeting this goal at both baseline and follow-up. Since goal HDL cholesterol
levels are different for males and females, mean HDL cholesterol and HDL cholesterol
control were further assessed by sex (Table 3.8). As expected, mean HDL cholesterol
levels were slightly higher in females than males. Although mean HDL cholesterol levels
were very similar between the intervention and control group, HDL cholesterol control
rates were slightly higher in females in the control group than the intervention group.
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Table 3.8. Mean HDL Cholesterol and HDL Cholesterol Control at Baseline and Follow-up By Group, Sex, and Diagnosis of Hyperlipidemia
INTERVENTION GROUP CONTROL GROUP
HLP Dx No HLP Dx All Patients HLP Dx No HLP Dx All Patients
MALES
N = 48 N = 5 N = 53 N = 47 N = 5 N = 52
HDL Cholesterol Levels
Mean ± SD (mg/dL)
Baseline 37.7 ± 7.3 33.6 ± 6.8 37.3 ± 7.3 37.1 ± 8.3 38.2 ± 6.1 37.2 ± 8.0
Follow-up 38.1 ± 7.0 31.6 ± 4.0 37.5 ± 7.0 38.0 ± 9.0 40.6 ± 6.5 38.3 ± 8.7
Difference 0.4 ± 4.6 -2.0 ± 3.7 0.2 ± 4.6 0.9 ± 6.6 2.4 ± 5.3 1.1 ± 6.5
HDL Cholesterol Control
N (%) Patients at Goal, HDL >40%
Baseline 16 (33.3%) 1 (20.0%) 17 (32.1%) 11 (23.4%) 2 (40.0%) 13 (25.0%)
Follow-up 15 (31.3%) 0 (0.0%) 15 (28.3%) 13 (27.7%) 3 (60.0%) 16 (30.8%)
FEMALES
N = 51 N = 14 N = 65 N = 47 N = 15 N = 62
HDL Cholesterol Levels
Mean ± SD (mg/dL)
Baseline 44.2 ± 13.8 54.7 ± 18.0 46.5 ± 15.3 48.4 ± 12.7 44.0 ± 10.8 47.4 ± 12.3
Follow-up 41.9 ± 13.8 53.6 ± 20.8 44.5 ± 16.2 47.6 ± 12.8 44.6 ± 10.8 46.9 ± 12.3
Difference -2.2 ± 7.4 -1.1 ± 8.4 -2.0 ± 7.6 -0.9 ± 6.5 0.6 ± 5.5 -0.5 ± 6.2
HDL Cholesterol Control
N (%) Patients at Goal, HDL >50%
Baseline 11 (21.6%) 7 (50.0%) 18 (27.7%) 19 (40.4%) 4 (26.7%) 23 (37.1%)
Follow-up 9 (17.6%) 7 (50.0%) 16 (24.6%) 17 (36.2%) 5 (33.3%) 22 (35.5%)
HLP = hyperlipidemia, Dx = diagnosis




Tables 3.9 shows that for diabetes medications, a greater increase in medication
adherence was observed in the control group than the intervention group, as measured by
both the medication possession ratio (MPR) and the percentage of patients with an MPR
≥80%; both measures approached statistical significance with P=0.059 and P=0.066,
respectively.
Evaluation of the number of unique medication classes that contributed to the
MPR calculations indicates that while patients in the control group maintained a
consistent 1.9 medications during the baseline and follow-up periods, patients in the
intervention were more likely to have additional medications added during the
intervention (2.3 medications at follow-up compared to 1.9 at baseline). The change in
number of medications was statistically significant (P<0.05).
Although adherence to insulin was not calculated, adherence to oral antidiabetic
medications may appear to decrease over time if patients switch from oral medications to
insulin therapy. Therefore, an assessment of the number and percentage of type 2
diabetic patients initiating insulin therapy during the follow-up period was conducted
(Table 3.10). No significant difference was seen in the percentage of patients initiating
insulin during the follow-up period (P=0.389).
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Table 3.9. Medication Adherence with Antidiabetic Agents and Mean Number of Medications Used
INTERVENTION CONTROL
GROUP GROUP
N = 79 N = 85
Medication Possession Ratio Significance Level
Mean ± SD (%)
Baseline 83.3 ± 0.2 75.8 ± 0.2
Follow-up 84.8 ± 0.2 83.8 ± 0.2
Difference 1.6 ± 0.2 8.0 ± 0.2
P=0.059a
Patients with MPR ≥ 80%
Number (%)
Baseline 54 (68.4%) 44 (51.8%)




Baseline 1.9 ± 0.8 1.9 ± 0.7
Follow-up 2.2 ± 0.9 1.9 ± 0.7
Difference 0.3 ± 0.7 0.0 ± 0.6
P<0.05a
Note: Calculations include oral antidiabetic medication and exenatide.
Analysis method:
a. Paired t-test, N = 57
b. Generalized linear model
Table 3.10. Insulin Use in Type 2 Diabetics at Baseline and Follow-up in Intervention and Control Groups
INTERVENTION CONTROL
GROUP GROUP
N = 104 N = 115
Patients Using Insulin Significance Level
Number (%)
Baseline 72 (69.2%) 59 (51.3%)
Follow-up 76 (73.1% 64 (55.7%)
Difference 4 (3.9%) 5 (4.4%)
P=0.389a
a. Analysis method: generalized linear model
68
Table 3.11 shows that for antihypertensive medications, a greater increase in
mean MPR was seen in the intervention group compared to the control group; the
difference was not statistically significant (P=0.212). However, the increase in
percentage of patients with an MPR ≥80% increased from 75.8% to 90.5% in the
intervention group, while the percentage decreased from 67.9% to 63.1% in the control
group. This difference was statistically significant (P=<0.05). Unlike the antidiabetic
medications, a similar change in the number of antihypertensive medications used from
baseline to follow-up was seen in both groups (P=1.000).
Table 3.11. Medication Adherence with Antihypertensive Agents and Mean Number of Medications Used
INTERVENTION CONTROL
GROUP GROUP
N = 95 N = 84
Medication Possession Ratio Significance Level
Mean ± SD (%)
Baseline 86.1 ± 0.2 82.3 ± 0.2
Follow-up 91.2 ± 0.1 83.2 ± 0.2
Difference 5.1 ± 0.1 1.2 ± 0.2
P=0.212a
Patients with MPR ≥ 80%
Number (%)
Baseline 72 (75.8%) 57 (67.9%)




Baseline 2.2 ± 1.2 2.1 ± 1.1
Follow-up 2.3 ± 1.3 2.3 ± 1.3
Difference 0.2 ± 0.5 0.2 ± 0.6
P=1.000a
Analysis method:
a. Paired t-test, N = 67
b. Generalized linear model
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Table 3.12 indicates that for antihyperlipidemic medications, no significant difference
was seen between the intervention and control groups in the increase in MPR (P=0.329), the
increase in the percentage of patients with an MPR ≥80% (P=0.845), or the change in number
of medications used (P=0.660) from baseline to follow-up.
Table 3.12. Medication Adherence with Antihyperlipidemic Agents and Mean Number of Medications Used
INTERVENTION CONTROL
GROUP GROUP
N = 71 N = 61
Medication Possession Ratio Significance Level
Mean ± SD (%)
Baseline 84.8 ± 0.2 76.2 ± 83.7
Follow-up 88.2 ± 0.1 83.7 ± 0.2
Difference 3.3 ± 0.2 7.4 ± 0.2
P=0.329a
Patients with MPR ≥ 80%
Number (%)
Baseline 48 (67.6%) 34 (55.7%)




Baseline 1.4 ± 0.6 1.2 ± 0.4
Follow-up 1.4 ± 0.5 1.3 ± 0.5
Difference 0.0 ± 0.4 0.1 ± 0.4
P=0.660a
Analysis method:
a. Paired t-test, N = 42
b. Generalized linear model
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Medication Persistence
Table 3.13 provides persistence with medications for diabetes, hypertension,
and hyperlipidemia, as measured by the mean days to discontinuation with medications
started within the first 120 days of the baseline and follow-up time periods. For all
three medication types, the days to discontinuation improved in the intervention group
compared to the control group; however, the differences were not statistically
significant.






Days to Discontinuation Significance Level
Mean ± SD N = 66 N = 74
Baseline 239.1 ± 99.4 228.8 ± 102.5
Follow-up 259.2 ± 94.6 210.1 ± 106.4
Difference 20.0 ± 131.2 -18.7 ± 125.0
P=0.226a
Hypertension
N = 88 N = 78
Baseline 248.1 ± 91.3 242.6 ± 96.0
Follow-up 241.7 ± 102.5 230.5 ± 103.4
Difference -6.4 ± 114.9 -12.1 ± 123.8
P=0.926b
Hyperlipidemia
N = 62 N = 55
Baseline 249.6 ± 93.0 222.8 ± 104.3
Follow-up 267.6 ± 82.4 238.6 ± 104.4
Difference 18.0 ± 113.0 15.8 ± 109.4
P=0.391c
Note: Diabetes calculation includes oral antidiabetic medications and exenatide.
a. Paired t-test, N = 42
b. Paired t-test, N = 56
c. Paired t-test, N = 29
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The percentage of patients remaining on therapy at 6 months is presented in
Figure 3.3. For diabetes medications, the percentage of patients remaining on therapy
increased from 68% to 85% in the intervention group, while it decreased from 61% to
57% in the control group. This difference approached statistical significance (P=0.050).














































Statistical testing method: generalized linear model
Diabetes: P=0.050, Hypertension: P=0.546, Hyperlipidemia: P=0.594
For hypertension medications, the percentage of patients remaining on therapy
decreased in both the intervention and control groups. Although the decrease was less in
the intervention than the control group, the difference was not statistically significant
(P=0.546). For hyperlipidemia medications, the percentage of patients remaining on
*P=0.05
N = 66 N = 74 N = 88 N = 78 N = 62 N = 55
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therapy increased in both the intervention and control groups. The difference between
the groups was not statistically significant (P=0.594).
Economic Measures
Patient Pharmacy Costs
Table 3.14 displays the total pharmacy costs, including both co-payments and
deductibles, paid by SWHP members, among patients who had a pharmacy cost in the
baseline or follow-up periods. Costs are categorized as those related to diabetes,
hypertension, hyperlipidemia, and “other”. As expected with the co-payment waiver for
diabetes medications and supplies in the intervention group, a significant difference in the
change in all diabetes-related member costs from baseline to follow-up was seen between
the intervention and control groups (P<0.05). No significant difference was seen in the
change in member costs for other medication types. Overall, a 37.2% reduction in patient
pharmacy costs in the intervention group and a 6.5% increase in patient pharmacy costs
in the control group was seen between baseline and follow-up.
Health Plan Pharmacy Costs
Table 3.15 presents the total health plan costs, categorized as those related to
diabetes, hypertension, hyperlipidemia, and other, for patients who had a pharmacy cost
in the baseline or follow-up periods. Similar to member costs, a significant difference
was observed in the change in all diabetes-related health plan costs from baseline to
follow-up between the intervention and control groups (P<0.05). In addition, the change
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N Median Mean [SD] Median Mean [SD] Median Mean [SD]
DIABETES
Insulin 76 $234.51 $276.14 [$271.70] $0.00 $9.03 [$21.14] -$234.51 -$267.11 [$272.39]*
Other DM Medicationsa 94 $73.84 $148.36 [$185.38] $0.00 $14.46 [$59.98] -$73.57 -$133.90 [$192.97]*
Diabetic Suppliesb 118 $101.04 $107.53 [$159.78] $0.00 $7.95 [$20.58] -$98.68 -$99.57 [$157.79]*
DIABETES TOTAL 118 $295.42 $403.57 [$351.56] $0.00 $25.29 [$63.54] -$288.40 -$378.28 [$356.79]*
HYPERTENSION
All HTN Medications 112 $98.09 $139.33 [$155.49] $120.14 $153.57 [$139.03] $11.36 $14.24 [$74.19]
HYPERLIPIDEMIA
All HLP Medications 96 $96.92 $140.44 [$188.68] $90.38 $145.21 [$193.02] -$2.16 $4.77 [$102.39]
OTHER
All Other Medications 115 $187.02 $267.97 [$314.01] $221.56 $290.59 [$324.48] $1.80 $22.63 [$162.59]
CONTROL GROUP
Baseline Follow-up Difference
N Median Mean [SD] Median Mean [SD] Median Mean [SD]
DIABETES
Insulin 64 $188.10 $190.41 [$136.40] $202.37 $240.66 [$225.29] $6.53 $50.25 [$221.55]*
Other DM Medicationsa 104 $71.94 $151.29 [$204.56] $91.42 $140.54 [$183.32] -$0.83 -$10.76 [$141.36]*
Diabetic Suppliesb 94 $59.55 $70.23 [$91.28] $60.08 $81.54 [$96.77] $2.62 $11.31 [$69.56]*
DIABETES TOTAL 118 $192.50 $292.56 [$296.29] $203.86 $319.35 [$318.51] $5.74 $26.78 [$210.24]*
HYPERTENSION
All HTN Medications 104 $89.81 $117.07 [$106.63] $106.20 $117.57 [$105.56] -$0.11 $0.51 [$76.32]
HYPERLIPIDEMIA
All HLP Medications 91 $86.68 $112.99 [$130.36] $66.66 $119.91 [$164.52] -$0.90 $6.92 [$106.81]
OTHER
All Other Medications 113 $136.71 $206.42 [$253.00] $151.20 $218.88 [$269.07] $3.09 $12.45 [$188.24]
DM = diabetes, HTN = hypertension, HLP = hyperlipidemia
a. Includes all oral prescription antidiabetic medications and exenatide.
b. Includes blood glucose monitors, test strips, lancets, and insulin syringes.
*P<0.05; paired t-test
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N Median Mean [SD] Median Mean [SD] Median Mean [SD]
DIABETES
Insulin 76 $1,054.00 $1231.27 [$1093.17] $1,921.12 $2431.70 [$1847.69] $863.04 $1200.44 [$1397.90]*
Other DM Medicationsa 94 $215.72 $416.36 [$562.43] $407.67 $1062.13 [$1162.93] $152.98 $645.77 [$896.17]*
Diabetic Suppliesb 118 $163.84 $213.71 [$344.46] $853.96 $794.18 [$564.01] $520.34 $580.47 [$436.31]*
DIABETES TOTAL 118 $1,031.61 $1338.41 [$1246.67] 2745.35 $3206.47 [$2290.98] $1,468.57 $1868.06 [$1590.73]*
HYPERTENSION
All HTN Medications 112 $108.92 $217.84 [$276.43] $104.34 $247.16 [$312.69] $3.71 $29.31 [$149.35]
HYPERLIPIDEMIA
All HLP Medications 96 $316.05 $378.45 [$389.30] $231.21 $299.02 [$340.61] -$20.80 -$79.43 [$351.25]
OTHER
All Other Medications 115 $215.90 $1168.57 [$3717.75] $423.25 $1372.45 [$4300.01] $45.45 $202.88 [$854.28]*
CONTROL GROUP
Baseline Follow-up Difference
N Median Mean [SD] Median Mean [SD] Median Mean [SD]
DIABETES
Insulin 64 $923.26 $1011.91 [$987.38] $1,178.80 $1292.43 [$1229.17] $151.76 $280.52 [$683.81]*
Other DM Medicationsa 104 $169.14 $486.52 [$775.80] $222.77 $462.66 [$764.49] $0.00 -$23.85 [$407.38]*
Diabetic Suppliesb 94 $152.23 $206.27 [$290.39] $213.70 $263.01 [$362.62] $1.14 $56.74 [$201.38]*
DIABETES TOTAL 118 $598.63 $1141.95 [$1356.60] $709.14 $1318.27 [$1548.23] $66.04 $176.33 [$686.64]*
HYPERTENSION
All HTN Medications 104 $84.73 $216.00 [$290.80] $92.90 $233.76 [$338.25] $4.19 $17.76 [$181.78]
HYPERLIPIDEMIA
All HLP Medications 91 $327.75 $401.38 [$433.50] $122.46 $247.46 [$311.47] -$25.91 -$153.91 [$378.84]
OTHER
All Other Medications 113 $175.42 $440.47 [$901.84] $216.23 $430.06 [$858.79] $0.84 -$10.41 [$264.01]*
DM = diabetes, HTN = hypertension, HLP = hyperlipidemia
a. Includes all oral prescription antidiabetic medications and exenatide.
b. Includes blood glucose monitors, test strips, lancets, and insulin syringes.
*P<0.05; paired t-test
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from baseline to follow-up in the cost of other medications was significantly different
between the intervention group ($202.88 ± $854.28) and the control groups (-$10.41 ±
$264.01; P<0.05). No significant difference was seen between the two groups in the
change in health plan costs for antihypertensive medications (P=0.552) or
antihyperlipidemic medications (P=0.416).
Table 3.16 shows the total health plan pharmacy costs for the entire study
population, categorized by group and medication type. While pharmacy costs increased
3.1% in the control group, costs increased 67.8% in the intervention group overall.
Diabetes-related costs and other medications were primarily responsible for the
difference in overall costs between the groups. Among the diabetes-related costs, the
largest increase in cost in the intervention group was in diabetic testing supplies
(271.6%), followed by non-insulin diabetic medications (155.1%), and insulin (97.5%).
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Baseline Follow-up Difference % Change Baseline Follow-up Difference % Change
DIABETES
Insulin $93,576.30 $184,809.48 $91,233.18 97.5% $64,762.26 $82,715.79 $17,953.53 27.7%
Other DM Medicationsa $39,138.14 $99,840.25 $60,702.11 155.1% $50,597.83 $48,117.10 -$2,480.73 -4.9%
Diabetic Suppliesb $25,217.84 $93,713.29 $68,495.45 271.6% $19,389.76 $24,723.38 $5,333.62 27.5%
DIABETES TOTAL $157,932.28 $378,363.02 $220,430.74 139.57% $134,749.85 $155,556.27 $20,806.42 15.4%
HYPERTENSION
All HTN Medications $24,398.45 $27,681.68 $3,283.23 13.5% $22,464.17 $24,311.05 $1,846.88 8.2%
HYPERLIPIDEMIA
All HLP Medications $36,331.02 $28,705.47 -$7,625.55 -21.0% $36,525.16 $22,519.19 -$14,005.97 -38.3%
OTHER
All Other Medications $134,385.87 $157,716.96 $23,331.09 17.4% $49,773.52 $48,596.68 -$1,176.84 -2.4%
TOTAL
All Medications $353,047.62 $592,467.13 $239,419.51 67.8% $243,512.70 $250,983.19 $7,470.49 3.1%
HTN = hypertension, HLP = hyperlipidemia
a. Includes all oral prescription antidiabetic medications and exenatide.
b. Includes blood glucose monitors, test strips, lancets, and insulin syringes.
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Total Pharmacy Costs
Total pharmacy costs, which include both member and health plan costs, are
presented in Figure 3.4. In the control group, costs remained relatively stable between
baseline and follow-up, but expenditures for insulin increased 28%, while those for
antihypertensive medications increased 25%. The amount paid for medications for
hyperlipidemia decreased by 29%.
In the intervention group, a substantial increase in expenditures for insulin (62%),
non-insulin diabetic medications (91%), and diabetic testing supplies (150%) was
observed. Also, increased expenditure was seen on other medications during the follow-
up period (16%). Similar to the control group, the expenditure on antihypertensive
medications increased slightly (12%), while a slight decrease in the amount paid for
antihyperlipidemic medications (-14%) was observed. Overall, total pharmacy costs
increased 43.3% in the intervention group and increased 3.9% in the control group from
baseline to follow-up.
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Diabetes-related Pharmacy Costs
Figure 3.5 compares each component of the diabetes-related costs (insulin, other
diabetic medications, and diabetic testing supplies) at baseline and follow-up in the
intervention and control groups. Although expenditure increased for all three
components in the intervention group, the greatest increase in expenditure was for
diabetic testing supplies, while the largest relative increase in expenditure in the control
group was for insulin.
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Factors Related to Achieving Glycemic Control
A multivariate logistic regression was conducted to determine factors related to
the achievement of goal A1C (<7%) at the end of the follow-up period (Table 3.17).
Covariates in the regression included study group, sex, age, diabetes type, improvement
in adherence with non-insulin diabetes medications, improvement in persistence with
non-insulin diabetes medications, start of insulin therapy, increased number of oral
diabetes medications, and increased use of diabetic testing supplies. Results of the
regression indicated that patients in the intervention group were approximately 8.7 times
more likely to achieve the A1C goal than control patients (P<0.05). All other variables
were not statistically significant.
Table 3.17. Logistic Regression of Achievement of Goal A1C at Follow-up
Variable Odds Ratio Sig. 95% CI
Adherence 0.86 0.791 0.27-2.67
Age: 35-44 years 1.30 0.748 0.27-6.34
Age: 45-54 years 0.67 0.515 0.20-2.22
Group 8.69 0.035 1.17-64.64
Insulin 3.04 0.434 0.19-49.23
Number of Medications 0.32 0.324 0.04-3.04
Persistence 0.75 0.622 0.24-2.33
Sex 0.65 0.464 0.20-2.07
Testing Supplies 0.22 0.156 0.03-1.78
Reference groups: Adherence= follow-up MPR ≤ baseline MPR; Age=25-34 years at study enrollment;
DM type=type 1 diabetes; Group=control; Insulin=no insulin initiated during follow-up period; Number
of medications=follow-up diabetes medication number ≤ baseline diabetes medication number;
Persistence=follow-up days to discontinuation ≤ baseline days to discontinuation; Sex=male; Testing
supplies=cost of follow-up diabetes testing supplies ≤ cost of baseline diabetes testing supplies
Note: DM type and Age 55-64 covariates removed from model due to redundancy.
Summary of Results
Tables 3.18-3.20 provide a review of the hypotheses tested and the study results.
81
Table 3.18. Summary of Hypotheses for Clinical Outcomes
Hypothesis Description Result Explanation
H01
There is no relationship between the change in
A1C from baseline to follow-up for patients
participating in the medication management
program and patients receiving usual care.
Rejected
A paired t-test showed a significantly greater decrease in
mean A1C in intervention patients (-1.1% ± 1.5%) than
control patients (-0.6% ± 1.8%; P<0.05).
H02
There is no relationship between the change in the
percentage of patients achieving goal A1C (<7%)
from baseline to follow-up for patients
participating in the medication management
program and patients receiving usual care.
Accepted
McNemar's test showed no significant difference in the
percentage of patients achieving A1C goal at follow-up in
the intervention group (16.1%) and the control group
(11.0%; P=0.345).
H03
There is no relationship between the change in the
percentage of patients with poor glycemic control
(A1C >9%) from baseline to follow-up for patients
participating in the medication management
program and patients receiving usual care.
Accepted
A generalized linear model showed that although a greater
reduction in the percentage of patients with poor glycemic
control was seen in the intervention group (45% at BL to
26% at FU) than the control group (55% at BL to 46% at
FU), the difference was not statistically significant
(P=0.163).
H04
There is no relationship between the change in the
percentage of patients achieving goal blood
pressure (BP <130/80) from baseline to follow-up
for patients participating in the medication
management program and patients receiving usual
care.
Accepted
A generalized linear model indicated no significant
difference between the groups in change in the percentage
of patients achieving in blood pressure control in the
intervention group (45.8% at BL to 46.6% at FU)
compared to the control group (45.0% at BL to 50.0% at
FU; P=0.737).
H05
There is no relationship between the change in the
percentage of patients achieving all goal
cholesterol levels (LDL <100, HDL >40 for males,
HDL >50 for females, total cholesterol <200,
triglycerides <150) from baseline to follow-up for
patients participating in the medication
management program and patients receiving usual
care.
Accepted
A generalized linear model indicated no significant
difference between the groups in change in the percentage
of patients achieving in cholesterol control in the
intervention group (11.0% at BL to 11.9% at FU)




Table 3.19. Summary of Hypotheses for Medication Adherence
Hypothesis Description Result Explanation
Accepted*
1) A paired t-test showed no significant difference in the change in MPR in the intervention
group (1.6 ± 0.2) and the control group (8.0 ± 0.2; P=0.059).
Accepted*
2) A generalized linear model showed no significant difference in the change in the percentage
of patients achieving MPR ≥80% in the intervention group (68.4% at BL to 67.1% at FU)
compared to the control group (51.8% at BL to 69.4% at FU; P=0.066).
Accepted*
3) A paired t-test showed no significant difference in the change in days to discontinuation in
the intervention group (20.0 ± 131.2) and the control group (-18.7 ± 125.0; P=0.226).
H06
There is no relationship
between the change in
adherence to
medications for diabetes







4) A generalized linear model showed no significant difference in the change in the percentage
of patients remaining on therapy at 6 months in the intervention group (68% at BL to 85% at
FU) compared to the control group (61% at BL to 57% at FU; P=0.050).
Accepted
1) A paired t-test showed no significant difference in the change in MPR in the intervention
group (5.1 ± 0.1) and the control group (1.2 ± 0.2; P=0.212).
Rejected
2) A generalized linear model showed a significant difference in the change in the percentage of
patients achieving MPR ≥80% in the intervention group (75.8% at BL to 90.5% at FU)
compared to the control group (67.9% at BL to 63.1% at FU; P<0.05).
Accepted
3) A paired t-test showed no significant difference in the change in days to discontinuation in
the intervention group (-6.4 ± 114.9) and the control group (-12.1 ± 123.8; P=0.926).
H07
There is no relationship










4) A generalized linear model showed no significant difference in the change in the percentage
of patients remaining on therapy at 6 months in the intervention group (75% at BL to 71% at
FU) compared to the control group (74% at BL to 64% at FU; P=0.546).
Accepted
1) A paired t-test showed no significant difference in the change in MPR in the intervention
group (3.3 ± 0.2) and the control group (7.4 ± 0.2; P=0.3.9).
Accepted
2) A generalized linear model showed a significant difference in the change in the percentage of
patients achieving MPR ≥80% in the intervention group (67.6% at BL to 77.5% at FU)
compared to the control group (55.7% at BL to 63.9% at FU; P=0.845).
Accepted
3) A paired t-test showed no significant difference in the change in days to discontinuation in
the intervention group (18.0 ± 113.0) and the control group (15.8 ± 109.4; P=0.391).
H08
There is no relationship











4) A generalized linear model showed no significant difference in the change in the percentage
of patients remaining on therapy at 6 months in the intervention group (75% at BL to 71% at
FU) compared to the control group (74% at BL to 64% at FU; P=0.546).
BL=baseline; FU=follow-up
*A significant increase in the number of medications used at FU compared to BL was observed in the intervention group.
Note: 4 methods were used to analyze adherence for each medication type.
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Table 3.20. Summary of Hypotheses for Pharmacy Costs and Achievement of Goal A1C
Hypothesis Description Result Explanation
H09
There is no relationship between the change in
patient pharmacy costs for
diabetes/hypertension/hyperlipidemia/other
medications and testing supplies for patients
participating in the medication management
program and patients receiving usual care.
Rejected
Paired t-tests showed no significant difference between the
groups in the change in patient pharmacy costs for
hypertension medications, hyperlipidemia medications,
and other medications; however, a significant difference
was seen between the groups in the change in patient
pharmacy costs for insulin, other diabetes medications,
and diabetic testing supplies.
H010
There is no relationship between the change in
health plan pharmacy costs for
diabetes/hypertension/hyperlipidemia/other
medications and testing supplies for patients
participating in the medication management
program and patients receiving usual care.
Rejected
Paired t-tests showed no significant difference between the
groups in the change in health plan pharmacy costs for
hypertension medications and hyperlipidemia medications;
however, a significant difference was seen between the
groups in the change in health plan pharmacy costs for
insulin, other diabetes medications, diabetic testing
supplies, and other medications.
H011
There is no relationship between the ability of
patients to achieve goal A1C (<7%) and study
group, sex, age, diabetes type, improvement in
medication adherence, improvement in medication
persistence, initiation of insulin therapy, increased
number of antidiabetic agents, or increased use of
diabetic testing supplies.
Rejected
A multivariate logistic regression revealed that,
controlling for factors such as sex, age, and diabetes type,
patients in the intervention group were approximately 8.7






In the general population, estimates indicate that 5-10% of diabetic patients have
type 1 diabetes.1 In this study population, however, nearly 12% of patients in the
intervention group and only 2.5% of the control group were type 1 diabetics. This
difference in the prevalence of type 1 diabetes between the two groups was statistically
significant (P<0.05).
The reason for the observed difference between the groups is difficult to ascertain.
While all patients were SWHP members, patients in the intervention were invited to
participate in the program and signed a consent form for study enrollment, while patients
in the control group were not aware of the research study, were randomly selected from a
similar population (that only knowingly differed from the intervention population in that
those subjects were treated at a different clinic location), and were matched to
intervention patients based on sex and age.
Since random selection of a control group yielded a significantly lower
percentage of type 1 diabetics than in the intervention group, this observation suggests
one or more of the following may be true:
1) The two patient populations differ in the prevalence of type 1 diabetes
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2) Type 1 diabetics were more likely to participate in the intervention than type 2
diabetics (due to patient willingness, physician recommendation, and/or early
screening and recruitment of type 1 diabetics)
3) Type 2 diabetics in the control group were more likely to have poorly
controlled A1Cs (>7.5%)
4) Type 1 diabetics in the control group were more likely to have well-controlled
A1Cs (≤7.5%)
5) Type 1 diabetics in the control group were less likely to be continuously
enrolled for two years than type 2 diabetics
Additionally, although a review of ICD-9 codes showed relatively similar
co-morbidities in the two groups, the intervention group generally had greater pharmacy
costs at baseline than the control group, particularly for insulin (as expected by the
greater proportion of type 1 diabetic patients) and “other medications.” This suggests
patients in the intervention group may have been slightly sicker or more likely to use
medications than control patients.
Clinical Measures
The mean A1C significantly improved in the intervention population compared to
the controls (-1.1% ± 1.6% vs. -0.6% ± 1.1%; P<0.05). The difference of 0.5% is similar
to, but slightly less than, two similar retrospective cohort studies evaluating pharmacist
interventions in type 1 and type 2 diabetic patients; those studies showed an average
difference of 0.75% and 1.0% in A1C improvement between intervention and control
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groups.63 In this study, the percentage of patients achieving goal A1C (<7%) and the
percentage of patients with uncontrolled A1C (>9%), although improved, were not
significantly better in the intervention group than the control group. These outcome
measures have not been reported in other studies.
Interestingly, no type 1 diabetic patients in the intervention achieved goal A1C.
The mean change in A1C for type 1 diabetic patients was -0.1%, whereas it was -1.1%
for the entire intervention group. This finding suggests that the program may not be as
effective in type 1 diabetic patients as in type 2 patients. Type 1 diabetics tend to be
diagnosed at a younger age; therefore, the educational component of this program may
not have been as useful for them, since those patients had been treated for a number of
years and may not have had as much to learn. Also, many of the educational materials
provided in the program were directed specifically toward type 2 diabetic patients. In
addition, a greater risk of a hypoglycemic episode exists with insulin – which all type 1
diabetics use – compared to oral antidiabetic medications. Therefore, type 1 diabetics
may strive to keep their A1C near the upper end of the recommended level to prevent
hypoglycemia.
Blood pressure measures remained relatively unchanged in both intervention and
control patients, with intervention patients achieving a 0.8 mmHg greater reduction in
systolic blood pressure and 0.3 mmHg greater reduction in diastolic blood pressure. A
similar study by Martin et al. (2004), which evaluated an intervention in which poorly
controlled diabetic patients (A1C >7%) met with a pharmacist for medication
adjustments every 6 weeks for a year, found a 4 mmHg greater reduction in systolic
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blood pressure and a 2 mmHg greater reduction in diastolic blood pressure.66 In this
study, change in the percentage of patients achieving goal blood pressure of <130/80 at
follow-up compared to baseline was not significant (P=0.737). This outcome measure
has not been reported in similar studies.
In this study, no significant difference was seen in the change in percentage of
patients achieving complete cholesterol control between the groups (P=0.268). This
outcome measure has not been evaluated in similar studies. The study by Martin et al.
(2004) found the mean LDL cholesterol decreased 9 mg/dL more in the intervention than
in the control group.66 In this study, the mean LDL cholesterol decreased 1.5 mg/dL
more in the intervention group than in the control group.
Adherence and Economic Measures
In general, this population was highly adherent with medications. It was expected
that the co-payment waiver for diabetic medications and testing supplies would increase
adherence to diabetic medications. Only two studies have evaluated adherence with
diabetic medications after a similar pharmacist-led intervention was implemented; both
found no significant improvement in adherence in the intervention group compared to
control patients.63 However, one major limitation of both studies was that patient
reporting was used to measure adherence. This methodology is not ideal since it is
subjective and may be limited by patient recall.
This study used pharmacy claims to evaluate medication adherence and generated
somewhat mixed results for adherence with diabetic medications; no significant
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improvement was seen in medication adherence in the intervention group compared to
the control group, as measured by the MPR (P=0.059). On the other hand, a significant
increase was seen in the number of medications taken in the follow-up period in the
intervention group compared to the control group. This finding suggests that patients in
the intervention group were more likely to be prescribed additional medications during
the intervention and/or patients in the intervention were more likely to fill and/or refill
medications due to the co-payment waiver.
As medication adherence has been shown to decrease with increased pill burden,
this observation may help explain why the improvement in MPR in the intervention
group was less than expected.67 Another possible explanation involves the design of the
program, in which patients were required to meet with a pharmacist each month to
receive a 30-day supply of medication(s). Studies have shown that patients who receive
90-day medication supplies generally have higher adherence rates than patients who
receive 30-day supplies.68 Assuming some patients participating in the intervention
previously received 90-day medication supplies, the change to a 30-day supply, along
with the necessity to attend an appointment with a pharmacist, may have contributed to
the less-than-expected increase in medication adherence for diabetic medications.
Medication persistence was evaluated as the percentage of patients remaining on
therapy at 6 months. In this study, the increase from 68% to 85% in the intervention
group was significantly different from the decrease from 61% to 57% in the control group
(P<0.05).
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For antihypertensive medications, improvement in MPR, the percentage of
patients with MPR ≥80%, days to discontinuation, and percentage of patients remaining
on therapy at 6 months was seen in the intervention group relative to controls. However,
the difference in the percentage of patients adherent with antihypertensive medications
(MPR ≥80%) was the only finding that was statistically significant (P<0.05). Both
groups used an average of 0.2 additional medications during the follow-up period.
Patient co-payment data support the theory that patients in the intervention are more
willing to pay for other medications, since those individuals have diabetic medication co-
payment waivers. However, the change in co-payment for antihypertensive medications
was not significantly different between the groups ($14.24 ± $74.19 vs. $0.51 ± $76.32;
P=0.167).
Adherence to medications for hyperlipidemia increased from baseline to follow-
up in both the intervention and control groups, as measured by the MPR, percentage of
patients adherent (MPR ≥80%), days to discontinuation, and percentage of patients
remaining on therapy at 6 months. No significant differences were observed between the
groups in the change from baseline to follow-up in any of the aforementioned measures,
or in the number of antihyperlipidemic medications taken. Patient co-payments and
health plan costs decreased for antihyperlipidemic medications during the follow-up
period, likely due to the introduction of the first generic HMG-CoA reductase inhibitor
into the market and the subsequent placement of the generic product onto the formulary
in late 2006-early 2007.
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The average annual increase in pharmacy costs during the time of this study was
approximately 7-8%.69,70 The data from this study generally reflect this trend, with a few
exceptions. The economic analysis showed a substantial increase in diabetes medications
and testing supplies in the intervention group, as would be expected with the medication
co-payment waiver and increased medication monitoring via monthly follow-up visits.
Additionally, the decrease in cost of antihyperlipidemic medications was likely due to
increased use of generic products.
Relative to the control group, the intervention group had a greater increase in
antihypertensive and other medication costs and a smaller decrease in cost of
antihyperlipidemic medications. Possible explanations for this finding are that the
medication co-payment waiver for diabetes medications may have made patients more
willing to fill other medications, the educational sessions may have made patients more
aware of the importance of adhering to medications, and/or the intervention patients may
have been a sicker population.
In an effort to evaluate the effectiveness of the medication management program
and control for confounding factors, a multivariate logistic regression was performed.
The results of the analysis showed that the intervention itself was the only factor which
significantly improved the likelihood of patients achieving glycemic control.
Limitations
 Patients were not matched on diabetes type. Significantly more type 1 diabetic
patients were enrolled in the intervention group than the control group.
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 The study methodology assumed the A1C goal for all patients was <7%. However,
some patients may have had a less-stringent A1C goal.
 The small sample size made it impossible to conduct some sub-analyses of interest
(i.e. type 1 diabetics vs. type 2 diabetics, patients taking medication vs. not taking
medication, etc.) and may be responsible for some of the non-significant results due
to insufficient power.
 Pharmacy and medical claims databases are generated for the purpose of collecting
payment for medications and medical services. When using pharmacy and medical
claims data for research purposes, many assumptions are made. For example, if a
patient fills a prescription for a medication, the assumption is that the patient will take
the medication. Similarly, it is assumed that a patient has the disease that a medical
service is billed under, although the visit may have actually been to rule out the
diagnosis.
 In this study, ICD-9 codes collected from the baseline year did not fully identify co-
morbid conditions in the population. For example, although it was known that all
intervention and control patients had a diagnosis of diabetes, only 11 of 17 patients
had an ICD-9 code for type 1 diabetes and 59 of 219 patients had an ICD-9 code for
type 2 diabetes. Therefore, a manual search of the electronic medical record was
conducted to determine diabetes type, as well as record of a hypertension or
hyperlipidemia diagnosis, as these were the co-morbidities of greatest interest in this
study. Other co-morbidities are likely highly underreported in the study results.
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 Change in clinical measurements may not be completely accurate due to the timing
and limited availability of the baseline and follow-up tests. For example, in the
intervention group, nearly all patients had a blood pressure measurement recorded on
the date of study enrollment, whereas baseline blood pressure measurements for
control patients came from the clinic visit nearest in date (generally within a month)
of the study enrollment date. Much greater variation was seen in the timing of A1C
measurements. Many baseline A1C tests were conducted greater than 3 months
before study enrollment in both the intervention and control groups. Thus, the tests
may not accurately reflect the patient’s glycemic control at the time of enrollment.
Fewer follow-up A1C and cholesterol tests were conducted in the control population
compared to the intervention group. In addition, an LDL cholesterol level was not
able to be calculated for many patients due to excessively high triglyceride levels.
 Patients may have seen physicians outside the SWHP network for treatment, and thus
medical record and laboratory information may not have been complete. For
example, for patients with missing A1C or cholesterol tests, a search of the electronic
medical record was conducted. Notes from outside physicians provided laboratory
values for four of these patients.
 Physician instructions for medication use were not available. Since this study
evaluated chronic conditions, it was assumed that once a patient initiated a
medication, those subjects would remain on the agent indefinitely. However, patients
may have been instructed to discontinue a medication.
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 It was assumed that all antihypertensive medications were used for hypertension and
should have been continued indefinitely. However, many antihypertensives are used
for other diagnoses, or in the case of some diuretics, may be prescribed as needed.
 The number of hospitalizations, office visits, and emergency department visits and
cost data were not available for analysis, but are necessary to truly measure the cost-
effectiveness of the intervention. Each patient’s ethnicity, duration of diabetes,
knowledge about diabetes, as well as the frequency of pharmacist-initiated
medication changes and incidence of adverse effects (i.e. hypoglycemia) would also
be useful and should be evaluated to determine if the study intervention is superior to
usual diabetes care.
 Patients who met the study inclusion criteria were invited to participate in the
medication management program. As this program required substantial commitment
with monthly appointments and also provided a potentially large monetary incentive
with the co-payment waiver, selection bias may have occurred.
 This study was conducted in high risk type 1 and type 2 diabetic patients (most recent
A1C >7.5%) within a managed care organization in central Texas. Results of this
study may not be generalizeable to other populations.
 Pharmacy and/or medical cost savings may not been seen during the first year of the
intervention as cost savings are expected to result from a relative reduction in the
utilization of medical resources in the long-run due to a slowed progression of
diabetes and/or a decrease in diabetes-related complications.
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Conclusion
The pharmacist-led medication management program significantly improved A1C
levels in intervention patients relative to controls. The intervention was more effective in
lowering A1Cs in type 2 diabetics than type 1 patients. Although the generalized linear
model showed that the intervention did not significantly improve the percentage of
patients achieving the ADA goal A1C of <7% compared to controls, the multivariate
logistic regression, which controlled for factors such as diabetes type, showed that
patients participating in the intervention were 8.7 times more likely to achieve the A1C
goal.
Persistence with diabetic medications and the number of medications taken
significantly increased in the intervention group; however, adherence rates, as measured
by MPR, did not significantly improve relative to controls. The expenditure on diabetic
medications and testing supplies increased substantially more in the intervention group
than in the control group. Whether or not the increased pharmacy cost was offset by
decreased medical costs is unknown.
Patients participating in the intervention were significantly more likely to become
adherent with their antihypertensive medications; however, this finding did not translate
into significantly better blood pressure control. For patients taking medications for
hyperlipidemia, adherence and persistence increased in both groups, while pharmacy
costs decreased in both groups. The introduction of the first generic HMG-CoA
reductase inhibitor during the study was likely responsible for this finding.
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CHAPTER FIVE: APPENDICES
APPENDIX I: Physician Letter and Patient List
(Insert Date)
Dear Dr. (Insert Last Name):
We are currently recruiting patients with diabetes to participate in a member benefit
medication management program. Enrollees in the program will also be eligible to
participate in a protocol which has received approval from the Scott & White Institutional
Review Board.
The Scott and White Health Plan in conjunction with the CDM Pharmacy will be
providing patients with information about diabetes and diabetes medications as well as
provide monitoring to help improve treatment of the disease. The program is designed to
improve medication and glycemic monitoring compliance as well as improve patients’
self monitoring skills. Participants in the program will have selected medication and
supply co-payments waived for the duration of their participation in the program.
Patients who meet the eligibility criteria will continue to qualify for these copay waivers,
for up to two years, as long as they continue to participate in the program.
Patients will be invited to participate via letter (see Appendices II and III). All patients
will be given a phone number to call if they have any questions regarding the service and
therefore should not need to contact your office.
After providing written agreement with the terms of the program, patients enrolling in the
medication management program will meet with a pharmacist monthly to review
medications and self-monitoring results as well as receive written and verbal educational
materials.
Enclosed is a list of your patients meeting the program criteria as identified by SWHP
claims databases. Screening criteria included the patient being 18 – 63 years of age,
utilizing more than $1200 per year of medications based on 2005 claims, and taking an
antidiabetic medication.
If you are not the physician provider for a patient, please check the column, “not my
patient”. In addition, if you know the patient’s physician provider, please list the
provider name in the appropriate column. If you identify additional patient names you
feel would qualify for the program, please submit their name and MRN or date of birth.
If you are aware of special circumstances such that this program and study would not be
beneficial to a particular patient, please circle the patient’s name on the enclosed
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sheet and fax the sheet to (254)215-9106 by _________. You may also reply by
emailing ttabor@swmail.sw.org or jjuan@swmail.sw.org. Feel free to contact Tricia
Tabor, Pharm.D. or Joyce Juan, Pharm.D. by telephone at 254-215-9117 (or T1 extension
219117) or pager 254-762-1067 (Tabor) or 254-762-3308 (Juan).
Thank you for your time in reviewing this list and also for your support of this new
program
and important research project.
The following is a list of your patients who are identified as possible candidates for the
medication management program and study. Please circle the name of any patient who would
not benefit from the program or the study. Again, thank yoSu for your involvement.
Patient Name MRN Not my
patient
If not your patient, please list primary
care provider if known
Please return by fax to 254-215-9106 or email (ttabor@swmail.sw.org or jjuan@swmail.sw.org).
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APPENDIX II: Medication Management Program Research Study Patient Letter
(Insert date)
Dear (insert patient name):
A research study is being done at Scott & White to look at the care of people with
diabetes. This study will look at a way to provide care and educate patients with
diabetes. This study will also look at how having diabetes affects the way people feel
about their health and well-being.
The study will last 2 years, and about 450 other people will be participating. This study
will evaluate the outcomes from involvement in the Medication Management Program.
The program is described in the attached letter from Scott & White Health Plan. The
people participating in the study will have the medical information that has been
collected during the course of the program evaluated and compared to medical
information from people who do not participate in a Medication Management Program.
You may choose not to be in the study, and your decision will not affect your care in any
way. Being in the study will not change the medical care you receive or the medications
you take.
Please indicate on the enclosed card if you are or are not interested in participating in the
study and mail the card back in the enclosed self-addressed, stamped envelope. If you
indicate on the card that you are interested in participating (or if you don’t return the
card), you will be contacted by telephone by one of the individuals conducting the study
within 10 days. The purpose of the phone call is to answer any questions you might have
and to discuss your possible participation.
Please feel free to contact the Scott & White number 1-254-215-9117 and leave a




APPENDIX III: Medication Management Program Patient Letter
Dear Scott & White Health Plan Member:
The Scott & White Health Plan is announcing a Member Benefit Medication
Management Program at the CDM Outpatient Pharmacy. We would like to invite you to
participate in this program. This program involves monthly meetings with the pharmacist
to help you better manage your diabetes. By participating in this program, you would also
receive your diabetes medications and testing supplies free of charge.
At the first appointment, the pharmacist would ask information from you about your
diabetes, medications, and lifestyle. Then you would meet with the pharmacist every
month to receive diabetes monitoring and education. The pharmacist would adjust the
doses of your diabetes medicines as needed as well as recommend diet and exercise
changes. The pharmacist would also monitor your blood pressure and cholesterol. This
type of pharmacist-led diabetes management service has been used in other areas of the
country and has been shown to improve patients’ health.
Although the main goal of this program is to improve your diabetes control, another
benefit of this program is that the co-pays for your diabetes medications would be
waived. You would receive your diabetes medications and testing supplies free of charge
if you follow the requirements of the program, which include the monthly appointments
with the pharmacist, laboratory tests, and regular visits to your primary care doctor. This
program requires a commitment from you to attend these appointments, but in return we
hope you will see improvement in your diabetes control.
Please indicate on the enclosed card if you are or are not interested in participating in the
program and mail the card back in the enclosed self-addressed, stamped envelope. If you
would like more information about this program or you would like to participate, you
may also contact the Scott & White Pharmacy at 254-215-9117.
If you indicate on the card that you are interested in participating (or if you don’t return
the card), you will be contacted by telephone by one of the pharmacists within 10 days to





APPENDIX IV: Authorization for Use and Disclosure of Health Information for
Research Purposes and Consent Form
CONSENT FORM and
AUTHORIZATION FOR USE AND DISCLOSURE
OF HEALTH INFORMATION for Research Purposes
Diabetes Outcomes Evaluation
SCOTT & WHITE CLINIC
SCOTT AND WHITE MEMORIAL HOSPITAL AND
SCOTT, SHERWOOD AND BRINDLEY FOUNDATION
TEMPLE, TEXAS 76508
You are being offered an opportunity to participate in a research study to evaluate the
effects of pharmacist counseling and education on the health and health care costs of
patients with diabetes. This is a non-funded research project. Neither the investigator nor
Scott & White will receive payment from an outside source for the costs related to the
conduct of this study.
Before you agree to volunteer to take part in this research study, it is very important that
you understand the purpose of the study and how health information about you may be
used or given to others during the study and after the study is finished.
Purpose and Background
The purpose of this research study is to test a method for improving control of diabetes.
You will be one of approximately 450 subjects in this research study. The method to be
evaluated is the Medication Management Program at Scott & White.
Procedures
You are eligible to participate in this study because you are eligible to participate in the
Medication Management Program. If you agree to participate in the study, the
information obtained during the Medication Management Program will be evaluated and
compared to the same information from patients who do not participate in the Medication
Management Program. This information will be gathered from your answers to
questionnaires, your answers to questions from the pharmacist, weight, height and blood
pressure measurements at the pharmacist visits, information from your Scott & White
medical record as well as information from your Scott & White health care claims. There
are no additional visits, tests, or medications needed by the research study.
Length of Study and Number of Visits
The study will last two years.
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Exclusions
You should not participate in this study if any of the following apply to you:
 you are unable to fill out the study surveys or communicate with the pharmacist
 you meet with the Medication Management Clinic currently or have met with the
clinic in the past 90 days.
Discomfort and Risks
The possible risk of this study is thought to be minimal. A breach of confidentiality of
your medical information could occur. For the purposes of the study, you will not be
identified by name, picture or any other personally identifying manner. The research
team will not release any data collected as part of this research that includes your name,
social security number, address, telephone number, health plan beneficiary information or
any other direct personal identifier, unless you have given permission for Scott & White
to do so.
Benefits
It is not anticipated that you would obtain direct benefit from the research study. The
possible benefits of this study are to show the benefits of the Medication Management
Program. These benefits could include improved control of diabetes, improved
satisfaction with care and treatment, and decreased health care costs.
Alternative Therapies
You have the alternative of not participating in this study. If that is the case you can
continue the routine care of your diabetes with your doctor. You also are able to continue
participation in the Medication Management Program.
Cost and Compensation
The research study does not require any additional visits with the pharmacist, laboratory
tests, or medications. There is no compensation for the research study.
New Findings
Any new findings developed during the course of your participation in the study, which
may be related to your willingness to participate, will be provided to you.
Termination of Subject Participation
Your participation may be terminated at any time by your physician and/or the
investigators without your consent. You may choose to leave the study at any time
without penalty or loss of benefits to which you are otherwise entitled.
Confidentiality
Study records that identify you will be kept confidential as required by law. The health
information that may be used and/or disclosed to conduct the study includes medical
records and information created or collected during your participation in the Medication
Management Program.
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Health information that identifies you will be used for medical, statistical and regulatory
purposes related to research. By agreeing to participate in this research, you are giving
authorization for the research team to use and report the results of treatments, tests and
examinations conducted for the Medication Management Program and for matters related
to study oversight and data analysis to:
 the Scott & White Institutional Review Board (IRB – a group of people who
strive to protect the rights of subjects)
 the Scott & White Research Compliance Office or Privacy Office.
 Scott & White employees involved in this study.
 local, state and federal agencies (such as the Office for Human Research
Protections and the U.S. Food and Drug Administration) when required by law.
Once health information about you has been disclosed to a sponsor or anyone outside of
this study, the information may no longer be protected by the federal privacy regulation.
The research team will not release any data collected as part of this research that includes
your name, social security number, address, telephone number, health plan beneficiary
information or any other direct personal identifier, unless you have given permission for
Scott & White to do so. You will not be identified by name, picture or any other
personally identifying manner if information from this study is presented publicly or
published in a medical journal.
Right to Withdraw Consent and Authorization
Participation in this study is voluntary. You may withdraw from participation and/or
revoke your authorization for the use of private information at any time during the study.
Your decision to withdraw and/or revoke your authorization will not result in any penalty
or loss of benefits to which you are entitled. Your decision will not affect the medical
care you receive at Scott & White.
You have a right to revoke your authorization. A request to revoke an authorization must
be submitted in writing to Tricia Tabor, Pharm.D., Scott & White Pharmacy, 1605 S. 31st
Street, Suite 19, Temple, Texas, 76508. Revoking your authorization only affects uses
and sharing of information collected after your written request has been received.
Information collected prior to revoking the authorization may continue to be used and
disclosed for research integrity and reporting purposes only.
Right to Access
You have a right to access your private health information, including health information
that is collected for the research. However, in order to protect the integrity of the study,
your right to access your research records may be suspended during the conduct of the
study. After the study is over (meaning the end of the whole study, not just your own
participation), you will be given access to these records upon your request.
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This Authorization does not have an expiration date.
Whom to Contact for Questions or Emergencies
If you have additional questions during the course of this study about your rights as a
research subject, you may address them to the IRB Office at (254) 724-4072. If you have
any questions about the research, please contact Tricia Tabor, Pharm.D., at (254)215-
9117.
If you have not already received a copy of the Notice of Privacy Practices, you may
request one. If you have any questions or concerns about your privacy rights, you should
contact the Scott & White Privacy Office at Ph: 254-724-7600.
Participation
Participation in this study is voluntary and refusal to participate will involve no penalty or
loss of benefits to which you are otherwise entitled. If you decide not to sign the
Authorization, you will not be allowed to participate in the research study.
Statement of Consent and Authorization
The research study has been explained to me and I have had an opportunity to read this
consent form/authorization and have all of my questions answered. I have been informed
that I may leave the study at any time without affecting my medical care and the Sponsor
or my doctor may withdraw me from the study without my consent. I freely agree to take
part in this research and authorize the research team to create, obtain, use or disclose
personally identifiable information in connection with this study. A signed copy of this
consent form/authorization will be given to me.
________________________ _______________________ _________
Printed Name of Subject Signature Date
Statement of Person Obtaining Consent
I have carefully explained to the subject the nature of the study. I hereby certify that to
the best of my knowledge the subject signing this consent form/authorization understands
clearly the nature, demands, risks and benefits involved in participating in this study. A
medical problem or language or educational barrier has not prevented a clear
understanding of the subject’s involvement in this study.
________________________ _______________________ _______
Printed Name of Person Signature Date
Obtaining Consent
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APPENDIX V: Diabetes Patient Education Materials
Scott and White Health Plan Member Benefit Medication Management Program
Diabetes Patient Education Pieces
Education topics:
Visit 1: Diabetes overview and goals
“What is Diabetes?” (TDC)
“Getting the Very Best Care for Your Diabetes”(ADA)
“Taking Care of Type 2 Diabetes” (ADA)
“Why Worry About Diabetes?” (NDEP)
Lab dates/results forms (NDEP)
Visit 2: Using glucometer/self-monitoring of blood glucose (SMBG)
“All About Blood Glucose for People with Type 2 Diabetes” (ADA)
“General Procedure for Self Blood Glucose Monitoring” (TDC)
When to call health care provider (TDC)
Blood glucose log (TDC)
Visit 3: Acute complications
Hypoglycemia and hyperglycemia picture charts (TDC)
“Examples of Treatments for Hypoglycemia” (NDEP)
Visit 4: Medication timing and administration
“Managing Your Medicines” (ADA)
“Insulin” timing and administering (TDC)
Visit 5: Nutrition, reading labels
“Basic Nutrition Guidelines for People with Diabetes” (TDC)
Food Pyramid (TDC)
MyPyramid.gov – individualized food pyramids (USDA)
Food labels, portion sizes (TDC)
“Food and Activity Tracker” (ADA)
Visit 6: Carbohydrate counting
“All About Carbohydrate Counting” (ADA)
Visit 7: Exercise
ADA – “All About Physical Activity for People with Diabetes”
NDEP – “Getting More Active – for People with Diabetes”
TDC – “Blood Sugar Limits for Exercise”
TDC – “How to Take Your Pulse”
TDC – “Leg Exercises for People with Diabetes”
Visit 8: Medications (mechanism of action/side effects/adherence)
“Oral Medicines” (TDC)
Visit 9: Chronic complications
“Complications of Diabetes” chart (TDC)
“Taking Care of Your Heart” (ADA)
“The SIMPLE Method for Preventing Diabetes Complications” (NDEP)
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“Warning Signs for Complications” (NDEP)
Visit 10: Foot care
“Foot Care for People with Diabetes” (TDC)
“Foot Care Tips” (TDC)
“Foot Care Checklist” (NDEP)
“Diabetic Food and Skin Care” (NDEP)
“Preventing Foot Injuries on the Job” (NDEP)
“Shoe Fitting Recommendations” (NDEP)
LEAP Program & monofilament (BPHC)
Visit 11: Psychosocial issues
“Learning How to Change Habits” (ADA)
“Changing Behavior” (TDC)
“Coping with Diabetes” (TDC)
“Lift Your Spirits” (NDEP)
“Facts about Depression” slides (NDEP)
“Recommended Readings for Coping with Diabetes and Depression” (NDEP)
Visit 12: Stress management
“Diabetes and Stress Management” (TDC)
“Stress” slides (signs, coping, management) (NDEP)
Stress test (NDEP)
Sources:
ADA = American Diabetes Association
BPHC = Bureau of Primary Health Care
NDEP = National Diabetes Education Program
USDA = United States Department of Agriculture
TDC = Texas Diabetes Council
Note: This is a general outline of educational topics to be discussed at each visit, when
applicable. For example, patients with type 1 diabetes will not receive educational
materials such as “All About Blood Glucose for People with Type 2 Diabetes,” rather,
they would learn about the importance and timing of measuring blood glucose as a type 1
diabetic.
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APPENDIX VI: Collaborative Practice Agreement
Scott & White Health Plan
Member Benefit Medication Management Program
Drug Therapy Management Protocol
This drug therapy management protocol is done to comply with the pharmacy and
medical practice acts regarding drug therapy management (DTM) by a pharmacist under
written protocol of a physician. The procedures, protocols, practices, and other items
contained within this document are intended to be helpful reminders for the pharmacists
and physicians of this institution. In no instance should the contents of this document be
considered as standards of professional practice or as rules of conduct or for the benefit
of any third party. This document is a guideline only and allows for professional
discretion and deviation where the individual healthcare provider deems variation to be
appropriate as allowed by law.
A. The individual physicians authorized to prescribe drugs and responsible for the
delegation of DTM are __________ of Community Internal Medicine (CIM) at
Scott & White Memorial Hospital.
B. The clinical pharmacist authorized to adjust or titrate medications under the
protocol and who will care out the DTM as delegated, is _______, Pharm.D.
C. Upon receipt of written consent from the patient and notification to the patient’s
primary care physician, and in accordance with the specified treatment guidelines,
the clinical pharmacist may provide pharmaceutical care in Scott & White Health
Plan pharmacies for enrolled patients under the protocol to include:
1. Assesses of patients’ therapeutic needs for disease states/ailments, which
include but are not limited to diabetes mellitus, hypertension, hyperlipidemia,
smoking cessation, and obesity.
2. Evaluates pharmacological and non-pharmacological treatment regimens.
3. Orders, interprets, and conducts all pertinent laboratory studies.
4. Adjusts medications in accordance with attached pharmacological privileges
(page 3).
5. The clinical pharmacist will not initiate or discontinue medications without
authorization from the physician.
6. Provides patient education regarding their disease state(s), pharmacological,
and non-pharmacological therapy, and medication adherence.
7. Performs pertinent physical assessments as a component of disease state
monitoring.
8. Documents patient visits, patient care, and treatment decisions in the medical
record. The patient’s primary care physician will have access to such medical
records.
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9. Consults with patient’s primary care physician and other members of the
health care team, as appropriate, to include ancillary services (podiatry,
dietary, social work) and ophthalmology.
10. Obtains authorization from the physician for deviations from the protocol.
11. This protocol does not delegate diagnosis to the clinical pharmacist.
12. The clinical pharmacist will utilize the most current version of treatment
guidelines for pharmaceutical care. These treatment guidelines include the
American Diabetes Association Clinical Practice Recommendations, the
Texas Diabetes Council Treatment Algorithm, American College of
Cardiology/American Heart Association Guideline Update for the Diagnosis
and Management of Chronic Heart Failure in the Adult, the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC), the National Cholesterol Education Program (NCEP),
National Asthma Education and Prevention Program (NAEPP) – written by
the National Heart Lung and Blood Institute (NHLBI); and the Global
Initiative on Asthma (GINA) and Global Initiative for Chronic Obstructive
Lung Disease (GOLD) – written by the NHLBI and the World Health
Organization (WHO).
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Clinical Pharmacist Drug Therapy Management Protocol:
Pharmacologic Privileges for __________, Pharm.D.
Level of Privileges:
A. Independent – no routine MD consultation required.
B. MD consultation required for initiating therapy.
Independent for renewing and adjusting.
C. Independent for renewal only.
D. MD consultation required.
NR. Not requested
A list of medications in each pharmacologic category may be found in the SWHP Formulary
LEVEL DRUG CATEGORY LEVEL DRUG CATEGORY
D ACNE PRODUCTS C ALZHEIMER’S MEDICATIONS
D ANAL/RECTAL PRODUCTS B ANALGESICS – NON-OPIOID
NR ANALGESICS – OPIOD NR ANTIARRHYTHMICS
NR ANTIMALARIALS D ANTIFUNGALS
NR ANTIVIRALS D ANTIMYCOBACTERIALS
C ANTIDEPRESSANTS D ANTIBIOTICS
B ANTIHYPERTENSIVES C ANTICONVULSANTS
B ANTIINFLAMMATORY/ANTIRHEUMATIC C ANTIHISTAMINES, NONSEDATING
NR ANTIPSYCHOTICS NR ANTINEOPLASTICS
NR ASSORTED CLASSES B ASTHMA-INHALTERS/NEBULIZERS
B ASTHMA – ORAL MEDICATIONS C BLOOD MODIFIERS
B CHOLESTEROL LOWERING AGENTS C CONTRACEPTIVES
B CORTICOSTEROIDS – ORAL NR CORTICOSTEROIDS – TOPICAL
C COUGH/COLD/ALLERGY PRODUCTS C DERMATOLOGICALS – ECZEMA/PSORIASIS
C DERMATOLOGICALS – MISC B DIABETIC AGENTS – MISC
B DIABETIC ORAL AGENTS B DIABETIC ORAL AGENTS – TZD
A DIABETIC SUPPLIES C ENDOCRINE – MISC
B GASTROINTESTINAL – LAXATIVES D GASTROINTESTINAL – ANTIEMETICS
C GASTROINTESTINAL – HEARTBURN/ULCER C GASTROINTESTINAL – INFLAM. BOWEL
C GASTROINTESTINAL – MISC NR GASTROINTESTINAL – DIGESTIVE ENZ.
C GOUT PRODUCTS B HEART/ANGINA MEDICATIONS
C HEMATOLOGICAL AGENTS NR HORMONES – ANDROGENS
C HORMONES – FEMALE NR IMMUNOSUPPRESIVE AGENTS
NR IMPOTENCE MEDICATIONS B INSULINS
A MEDICAL DEVICES C MIGRAINE PRODUCTS
D MOUTH & THROAT TOPICAL PRODUCTS NR MUSCLE RELAXANTS
A MULTIVITAMINS B NASAL PRODUCTS
NR NEUROMUSCULAR DRUGS – MISC. A NUTRITIONAL – PRESCRIPTION VITAMINS
B NUTRITIONAL – MINERALS & ELECTROLYTES D OPHTHALMIC AGENTS
D OTIC AGENTS C OSTEOPOROSIS DRUGS
B PROSTATE MEDICATIONS C PARKINSON’S DRUGS
NR SEDATIVE/HYPNOTICS/ANTIANXIETY NR PSYCHOTHERAPEUTIC AGENTS – MISC
B THYROID MEDICATIONS NR STIMULANTS
C URINARY AGENTS – ANTISPASMOTICS D URINARY AGENTS – ANTIINFECTIVES
A VACCINES C URINARY AGENTS – MISC
A OTCs (ANY CLASS) C VAGINAL PRODUCTS
____________________________ __________________________________
Requesting Practitioner / Date CIM Clinic Supervising Physician / Date
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APPENDIX VII: SWHP Insurance Contract Waiver
Scott & White Health Plan Medication Management Program – Diabetes
Scott & White Health Plan Insurance Contract Waiver
Name: DOB:
Address: PCP:
Home phone: Work/cell phone:
E-mail address:
I agree to voluntarily participate in the Scott & White Health Plan Member Benefit
Medication Management Program for Diabetes. I understand that I will be required to
comply with proposed elements of this program, which are guided by the Texas Diabetes
Council and American Diabetes Association guidelines which include but are not limited
to: 12 visits with a pharmacist at the CDM Outpatient Pharmacy prior to beginning of the
program and at one month intervals; regular visits to my primary care physician (PCP) as
deemed necessary; laboratory tests and life style modifications.
I understand that for my participation, the prescription drugs and supplies listed in
Appendix A of this document will be available to me free at a $0 copayment. These
prescription drugs and supplies will be dispensed in 30-day supply quantities and must be
obtained at the Scott & White CDM or South Loop pharmacies in order to receive this
benefit of participation. Prescription drugs and supplies not listed in Appendix A or used
for the treatment of other conditions besides diabetes are not included in this program.
I understand that failure to keep appointments with my PCP or pharmacist, to comply
with recommendations for laboratory tests, or to pick up my prescription drugs will result
in dismissal from this program. Dismissal from the program will occur 30 days after
written notification, which will be sent to my home address by certified mail, unless the
identified compliance failure is corrected and appropriate visit(s) are rescheduled to occur
within 15 days of the original appointment date. Dismissal will occur upon absence from
one unexcused appointment without prior notification as described above. Once
dismissed, the co-payments for the prescription drugs listed in Appendix A will revert
back to my contractually defined co-payments according to the guidelines and limitations
of my current Evidence of Coverage (EOC). Exceptions will be made to this dismissal
policy if extenuating circumstances occur which include personal medical emergencies
and unexpected hospitalizations at the time of my appointment.
Scott & White Health Plan reserves the right to cancel this program at any time with 30
days notice to all participants. This program is available only to those who are current
members of Scott & White Health Plan and will not be continued if your eligibility
ceases.
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I give permission to Scott & White personnel to access my medical and prescription
records at Scott & White for the purposes of this program.
Signature _____________________________ Date _____________________
Scott & White Health Plan Medication Management Program – Diabetes
Scott & White Health Plan Insurance Contract Waiver



































APPENDIX VIII: Classification of Medications Used to Measure Medication
Adherence and Persistence: Medications for Diabetes, Hypertension, and
Hyperlipidemia
DIABETES MEDICATIONS
Medication Class Generic Name Study Classification
α-Glucosidase Inhibitor Acarbose α-Glucosidase Inhibitor
Biguanide Metformin Biguanide
Dipeptidyl Peptidase IV Inhibitor
(DPP4)
Sitagliptin DPP4
Incretin Mimetic Exenatide Incretin Mimetic
Sulfonylurea (SFU) Glimepiride SFU
Glipizide
Glyburide
Thiazolidinedione (TZD) Pioglitazone TZD
Rosiglitazone
Combination Products Metformin/Sitagliptin Biguanide + DPP4
Metformin/Glipizide Biguanide + SFU
Metformin/Glyburide Biguanide + SFU
Metformin/Pioglitazone Biguanide + TZD
Metformin/Rosiglitazone Biguanide + TZD
HYPERTENSION MEDICATIONS
Medication Class Generic Name Study Classification
Alpha Blocker Doxazosin Alpha Blocker
Terazosin Alpha Blocker
Alpha-Beta Blocker Carvedilol Alpha Blocker + BB
Labetalol Alpha Blocker + BB
Angiotensin Converting Enzyme Benazepril ACEi







Medication Class Generic Name Study Classification















Direct Renin Inhibitor (DRI) Aliskiren DRI
Diuretic: Thiazide-like (TLD) Chlorthalidone TLD
Hydrochlorothiazide TLD
Metolazone TLD
Duretic: Loop (LD) Ethacrynic Acid LD
Furosemide LD
Torsemide LD




Combination Products Benazepril/Amlodipine ACEi + CCB
Lisinopril/Hydrochlorothiazide ACEi + TLD
Losartan/Hydrochlorothiazide ARB + TLD
Olmesartan/Hydrochlorothiazide ARB + TLD
Valsartan/Hydrochlorothiazide ARB + TLD
Bisoprolol/Hydrochlorothiazide BB + TLD
Metoprolol/Hydrochlorothiazide BB + TLD
Propranolol/Hydrochlorothiazide BB + TLD
Amiloride/Hydrochlorothiazide PSD + TLD
Spironolactone/Hydrochlorothiazide PSD + TLD
Triamterene/Hydrochlorothiazide PSD + TLD
Hydralazine/Isosorbide Dinitrate Vasodilator + Other
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HYPERLIPIDEMIA MEDICATIONS
Medication Class Generic Name Study Classification










Nicotinic Acid (NA) Niacin NA
Omega-3 Fatty Acid Omega-3 Acid Ethyl Esters Omega-3 Fatty Acid
Resin Cholestyramine Resin
Colestipol Resin
Combination Products Ezetimibe/Simvastatin CAI + Statin
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APPENDIX IX: ICD-9 Codes Used to Identify Diabetes and Diabetes-related
Co-morbidities
ICD-9 Codes Condition
250.xx, 357.2x, 362.0x, 366.41 Diabetes
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